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General anaesthetics cause widespread neurochemical and physiological 
changes in the brain. However, the precise mechanism of amnesic action is 
largely unknown. Gene expression changes in the hippocampus have been a 
focal point for investigation in this area, while effects on the cerebral cortex 
have been largely underreported even though the cerebral cortex has been 
shown to play a large role in memory consolidation and storage. Amnesia is 
likely due to the change in expression of memory-related genes within the 
neocortex or hippocampus of the mammalian brain.  
 
The first aim of this research was to investigate the in vitro cortical gene 
expression pattern of two memory-related genes; activity-regulated 
cytoskeleton-associated protein (Arc) and brain-derived neurotrophic factor 
(Bdnf), after a t=4 hour exposure to propofol- or sevoflurane- induced 
anaesthesia using an adult mouse brain slice model and real-time quantitative 
PCR. Five animals were used for each anaesthetic and a t=0 hour control, 
t=4 hour control and t=4 hour treated 400 µm slice were taken from each 
animal. Seizure-like activity was recorded from the brain slices to ensure 
viability of the tissue before carrying out the anaesthetic exposure. RNA was 
extracted, DNAse-treated, and then converted to cDNA. Quantitative PCR was 
then carried out to analyse Bdnf and Arc expression differences between the 
t=4 hour control and t=4 hour treated samples using Gapdh, β2m, Actb and 
HRPT1 as reference genes. The second research aim was to determine the 
Bdnf protein expression level and localisation after a t=4 hour exposure to 
propofol using western blot and immunohistochemistry methodologies. 
 
Our research demonstrated that Arc was significantly down-regulated after 
exposure to sevoflurane for t=4 hours (p<0.05). Arc was also shown to be 
up-regulated after a t=4 hour exposure to propofol while Bdnf showed a 
downregulation to sevoflurane but an upregulation to propofol, however this 
 
ii 
data was not statistically significant. Western blot data showed that the rabbit 
polyclonal Bdnf antibody was binding to an off-target epitope at 55 kDa with 
mouse brain, heart, lung, liver, spleen and kidney whole tissue lysate. A newly 
sourced commercial Bdnf antibody was validated and western blot data 
showed recognition of the Bdnf epitope at the correct predicted size of 28 kDa 
in the mouse brain, heart and kidney. Immunohistochemistry of frozen mouse 
brain sections failed to produce a positive signal for two different Bdnf 
antibodies due to encountering technical issues. Hematoxylin and Eosin 
staining showed the tissue was still intact after the sectioning procedure. These 
issues could be resolved in the future by improving the tissue fixation length 
and optimising the antigen retrieval step. 
 
Eleven recommendations have been made to provide further insight into the 
gene expression levels of memory-related genes in the mouse brain. This 
includes varying the induction and maintenance of the two anaesthetic drugs, 
role of epigenetic modification, evaluating the mental state of the mice 
(depression), investigating Bdnf knockout, differential expression between 
areas of the brain and brain electrical activity. In addition, the gene expression 
pattern after a period of anaesthetic exposure should also be analysed. This 
may help elucidate the causes of postoperative cognitive dysfunction. Whole 
transcriptome analysis using RNA-Seq could be used to determine the 
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Anaesthetics, from the Greek anaisthēsia (an- meaning without and aisthēsia 
meaning sensation), are a range of drugs used during surgery to bring about 
reversible loss of consciousness, analgesia, areflexia and amnesia. They are 
paramount in medicine today as they enable the performance of long, painful 
surgeries without the interference of the patient’s pain or reflexes. General 
anaesthetics were first discovered in 1842 by Crawford Long of Athens, 
Georgia, USA. Long repeatedly used ether to operate without pain, yet he did 
not publicise this discovery. General anaesthetics were introduced to the public 
in 1846 by Dr. William Morton, an American dentist 1, 2. Morton demonstrated a 
surgery where a patient was under complete anaesthesia by using the volatile 
gas, diethyl ether in the correct dose, to a group of influential surgeons at 
Massachusetts General Hospital, USA. Another commonly used inhalation 
anaesthetic was nitrous oxide. These early inhalation anaesthetics had many 
adverse effects on the patients, for example, vomiting and nausea. 
 
In 1932, sodium thiopental was the first intravenous (IV) anaesthetic to be used 
3. This had a larger therapeutic range and less undesirable side effects post 
operation. Intravenous anaesthetics therefore opened up safer avenues to 
anaesthesia 4. In the mid-1900s isoflurane became popular due to the quick 
recovery from unconsciousness. Isoflurane however was not used to induce 
anaesthesia, as it commonly irritated throats 5. Thus, sodium thiopental was 
initially used to induce the patient, followed by the use of isoflurane to maintain 
the anaesthesia. In 1971 Dr. Ross Terrell of New York, USA synthesised 
sevoflurane, which had quick induction times, less chance of throat irritability, 
fewer cardiovascular depressant effects and slightly faster recovery times 6. 
The reduction in throat irritability enabled sevoflurane to be used as an 
 
2 
induction and maintenance anaesthetic. Propofol was first developed in 1976 
by Imperial Chemical Industries, London, UK and has largely replaced sodium 
thiopental as an IV induction anaesthetic due to patients having a more rapid 
recovery 4. Although propofol is most often used for induction, it can also be 
used for maintenance. 
 
For over a hundred years general anaesthetics have been used to eliminate 
pain during surgery, yet little is known about their biochemical pathways or how 
they produce amnesia. Brain activity during anaesthesia can be recorded using 
an electroencephalogram (EEG). This does not show the molecular effects 
within the brain, or why amnesia is a postoperative side effect. The side effects 
of anaesthetics can range from something as simple and common as nausea 
or a sore throat to severe and very rare effects, such as intraoperative 
awareness or death 7. One of the most common side effects is amnesia, and 
just like the molecular pathways of the anaesthetic agents, little is known about 
how amnesia is brought about. Although amnesia is required for a successful 
surgery, it becomes a disadvantageous and detrimental post-surgery side 
effect where it can play a role in postoperative cognitive dysfunction. 
Intraoperative awareness is when the patient regains consciousness or can 
recall events during the surgery and is one of the reasons why amnesia is 
required for surgery. As a result, this can lead to posttraumatic stress disorder 
(PTSD) surrounding the events of the surgery, thus amnesia is advantageous. 
Intraoperative awareness is a serious complication with 20,000 to 40,000 of the 
4 million surgical patients in the USA being affected 7, 8. 
 
Research into changes in the brain caused by general anaesthetics has 
predominately investigated the physiological and neurochemistry aspects, 
which includes blood flow, electrical activity and energy metabolism 9. With the 
availability of modern techniques, for instance, microarray and full 
transcriptome sequencing, it has been shown that from a microarray consisting 
of 2596 detected transcripts, 417 genes had their expression levels changed 
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by at least two-fold, in the rat hippocampus, after a clinical dose of the general 
anaesthetic sevoflurane. The vast majority of genes showed a decrease in 
expression and over 20% of these were related to cellular metabolism or 
primary metabolism 10. Because of this large variety of proteins that are 
affected, amnesia could be the result of expression changes in memory-related 
genes. 
 
Clinical dosage levels for the volatile general anaesthetics; isoflurane and 
sevoflurane vary between 1 – 3% depending on the weight of the patient but 
also the accompanying gases 11. Lower doses are needed with a nitrous 
oxide/oxygen mix while higher doses are needed when using just oxygen. This 
clinical dose is what is needed for the reversible loss of consciousness, but 
loss of consciousness is not required for cognitive dysfunction and amnesia. 
Doses as low as 0.7% isoflurane or 1% sevoflurane have been shown to bring 
about cognitive dysfunction and memory loss 7. At these doses the patient may 
not be completely unconscious and can even be aware of their surroundings. 
Similar results have been shown with sevoflurane where a clinical dose of 
between 2 and 2.5 mg/kg is required to induce anaesthesia while memory loss 
can occur at 1.9 mg/kg 12. 
 
Side effects may not just present themselves during anaesthesia or directly 
after, but may persist for weeks after anaesthesia is administered. 
Postoperative cognitive dysfunction (POCD) is a temporary decline in cognitive 
function over a period of a few days to a few weeks, post operation. The 
symptoms include amnesia, confusion, reduced awareness, and attention. 
Postoperative cognitive dysfunction is a growing problem in medicine today, 
due to an aging population with higher susceptibility of elderly persons 13, 14. 
The cause of POCD is unknown, but general anaesthetics have been shown 
to affect gene expression greatly even 48 hours after anaesthesia, 9. As a 
result, expression changes could continue for days or weeks. General 
anaesthetics have also been shown to reduce the number of synapses in 
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developing rodents and non-human primates 15, 16. This is of great importance 
as pediatric patients that go under anaesthesia for extended periods of time 
can be affected by anaesthetic neurotoxicity and irreversible damage 17.  
 
This study investigates how two general anaesthetics; propofol and 
sevoflurane effect gene expression using an in vitro mouse model. Primary 
targets will be candidate memory-related genes, Bdnf and Arc. 
 
1.1 Memory Consolidation 
 
The mammalian brain is a complex organ involved in information processing, 
perception, motor control, arousal, homeostasis, motivation and most 
importantly; memory and learning 18. The neocortex of the brain has been 
shown to play a role in memory and learning processes 19. 
 
Communication within the brain occurs between neurons, which consist of a 
soma, dendrites and an axon 20. Each neuron has one axon protruding from its 
soma. The connections between a neuron axon terminal and another neuron’s 
dendrites are called synapses. Synapses are the connection point between the 
presynaptic neuron axon terminal and the postsynaptic neuron dendrite 
(Figure 1). Synapses enable neurons to communicate with each other using 
chemicals as signaling molecules 21. These molecules are known as 
neurotransmitters. The axon terminal releases neurotransmitters, and 
dendrites have receptor proteins that recognise the different neurotransmitters. 
There are excitatory and inhibitory neurotransmitters. Glutamate is often the 
excitatory neurotransmitter and binds to the N-methyl-D-aspartate (NMDA) 
receptor or the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) 
receptor. Gamma-aminobutyric acid (GABA) is the inhibitory neurotransmitter 





Figure 1: Synapse between Two Neurons.  Diagram shows the neurotransmitters (red, 
yellow, blue circles), their transporters and receptors of the presynaptic neuron (left) and 
postsynaptic neuron (right) 24. 
 
Neurons are able to communicate with each other by using action potentials 
which are propagated along the axon and received by a synapse 23. An 
excitatory signal results from a flow of positively charged ions into the neuron 
or negatively charged ions out of the neuron. Inhibitory signals are the opposite; 
a flow of negatively charged ions into the neuron or positively charged ions out 
of the neuron. For a neuron to pass an excitatory signal to another neuron it 
must reach a net excitation before the signal will travel down the axon. 
Excitatory and inhibitory synaptic signals therefore act against each other and 
a neuron must receive enough excitatory signals to propagate the signal. 
However, if the neuron also receives inhibitory signals, the net excitation may 
not be high enough to continue the synaptic excitation. This is how the brain 
reacts and decides what to do after receiving information from many different 
stimuli. When both the presynaptic and postsynaptic neurons are continuously 
activated, the synaptic connection is strengthened and this is thought to be the 




Memory can be considered as short-term or long-term depending on the brain’s 
ability to recall the information. Short-term memory, or working memory, only 
lasts 20 to 30 seconds so it must be ‘saved’ 25. This process is called 
consolidation and occurs when there is repetition of a memory. When the same 
presynaptic neurons are continuously releasing neurotransmitters, while the 
postsynaptic neuron receptors are being activated, the synaptic connection is 
strengthened. A synaptic connection can also be strengthened by an increase 
in the number of postsynaptic neurotransmitter receptors, causing the neuron 
to respond more efficiently to the neurotransmitters. This is the basis for the 
synaptic plasticity as a mechanism for memory consolidation 24. 
 
1.2 Synaptic Plasticity and Long-Term Potentiation 
 
Synaptic plasticity is the strengthening or weakening of the synapses from 
varying levels of activity, whereas, long-term potentiation (LTP) is the 
continuous re-enforcement of synapses due to current activity levels. Memory 
is a result from the permanent modification of the synapses between cortical 
neurons activated by a particular event. Synaptic plasticity and LTP are thought 
to be the underlying mechanisms for memory consolidation. The biochemical 
pathway that initiates LTP induction starts with glutamate binding to the NMDA 
receptors, causing calcium (Ca2+) to enter the neuron, while the postsynaptic 
membrane is depolarised. The elevated Ca2+ levels activate protein kinases 
which phosphorylate specific substrate proteins, such as AMPA receptors to 
increase their activity, leading to the enhanced synaptic effectiveness 19, 26. To 
gain LTP, a critical level of Ca2+ must enter the neuron through the NMDA 
receptor channel. If this level is not reached then long-term depression (LTD) 
will occur in the activated synapses. LTD is the opposite of LTP: where LTP is 
a long lasting signal transmission between two neurons that are stimulated at 
the same time, LTD is the reduction in efficacy of neuronal synapses. LTD 
remains stable for many hours without any sign of decay, just like LTP. 
Therefore, LTD can store information long enough to contribute to hippocampal 




LTP and LTD are perpetuated by synaptic strengthening or synaptic plasticity. 
This enables the synapses between specific neurons to be strengthened and 
therefore causes a stronger response to a specific stimuli. Short-term memory 
was shown to not be consolidated into long-term memory when protein 
synthesis inhibitors were given to goldfish (Carassius auratus) 25. This supports 
the hypothesis that synaptic plasticity requires synthesis of de novo 
neurotransmitter receptor proteins. Short-term memory formation still occurred 
with protein inhibitors present, showing that short-term memory does not 
require synaptic strengthening. Post-translational protein modification, like the 
phosphorylation of AMPA receptors for increased activity, is also part of 
synaptic strengthening. This would still occur with protein synthesis inhibitors, 
yet memory was still unable to be consolidated. Therefore the synaptic 
plasticity is not caused from just an increase in receptor proteins or 
post-translational protein modification of memory-related proteins, but a 
combination of both 25. 
 
1.3 The Cerebral Cortex 
 
The cerebral cortex is the outer most layer of the mammalian brain and contains 
the neocortex (Figure 2) 27. It is grey matter consisting mainly of neuronal cell 
bodies and capillaries. Under this is white matter, which consists mainly of 
white myelinated sheaths of neuronal axons; thus, resulting in its white colour. 
The cerebral cortex folds into bulges called gyri and valleys called sulci. These 
folds are due to the placement of the neuronal bodies in the cerebral cortex 
and the axons in the white matter. This increases the surface area, thereby 







Figure 2: Cerebral Cortex on a Coronal Section of a  Mouse Brain.  The cerebral cortex 
is the outermost layer of the brain (red). 
 
The neocortex is the largest part of the cerebral cortex, spanning the two 
cerebral hemispheres, and is differentiated into six layers; I-VI. These layers 
were first described by Korbinian Brodmann in 1909, however Santiago 
Ramón y Cajal was awarded the Nobel Prize in Physiology or Medicine in 1906 
for his work in the structure of the nervous system including the cerebral cortex 
(Figure 3) 18, 28. Layer I consists predominately of dendrites from pyramidal 
neurons, glial cells and axons from stellate cells; whereas, Layer II contains 
mostly small pyramidal and stellate cells. Layer III has larger pyramidal neurons 
with axons that reach all the way down into the white matter. Layer IV is made 
up of closely packed stellate cells and, also in this layer a large number of 
horizontally oriented fibers form a white band. Layer V is composed of large 
pyramidal cells with few stellate cells and another band of horizontal fibers. 
Finally, layer VI consists of pyramidal cells again, but with a fusiform shape, 
which are large in the middle and taper off at both ends. The cerebral cortex is 
most notably involved in short-term memory. However, the medial temporal 






Figure 3: Drawing of the Layers of the Cerebral Cor tex by Santiago Ramón y Cajal.  
A) Nissl-staining (endoplasmic reticulum staining) of the visual cortex of a human adult. B) 
Nissl-stained motor cortex of a human adult. C) Golgi-stained (dendrites and cell soma 
staining) cortex of a 1 ½ month old infant 30. 
 
1.4 Physicochemical and Pharmacodynamics of General  
Anaesthetic Agents 
 
1.4.1 Propofol  
Propofol (2,6-di(propan-2-yl)phenol) is a phenolic derivative general 
anaesthetic, but it is not structurally related to other barbiturates – the classic 
class of central nervous system (CNS) depressant drugs (Figure 4). Propofol 
is a useful general anaesthetic due to its rapid onset and short duration of 
action 31. Because it is a liquid, it is introduced intravenously and can be used 
by itself to both induce and maintain anaesthesia. Propofol has a 
dose-dependent effect on patients, ranging from mild sedation to complete 
general anaesthesia. At low dosage levels, it can produce amnesia and it has 
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been given the name “milk of amnesia” due to this property 31. As propofol is 
highly lipophilic, it is able to penetrate the blood-brain barrier quickly, resulting 
in its rapid onset. This rapid penetration and amnesic side effect makes 
propofol a great candidate for studies of gene expression in the brain. 
 
 
Figure 4: Chemical Structure of Propofol  32. 
 
The mechanism of action for propofol is unknown, but thought to be through 
the activation of GABAA receptors, either through direct interaction with the 
receptor or by modulating GABAA receptor activity 33. NMDA receptors are 
inhibited by propofol, by preventing the movement of Ca2+ into neuronal cells. 
A calcium influx within cells causes the activation of proteases, lipases and 
endonucleases, which can damage neurons. Propofol can therefore act as a 
neuroprotective agent by inhibiting the NMDA receptors 32. 
 
Concentrations of 27.5 mg/kg propofol show that LTP is reduced 10-minutes 
post tetanus stimulation in mouse brain slices of the hippocampus region. This 
reduced potentiation is also evident immediately after tetanus stimulation, but 
to a lesser extent. At concentrations of 11 mg/kg and below, this reduction in 
potentiation does not occur. LTD is not affected at any concentration of 
propofol. Clinical use of propofol requires a concentration of between 2 and 
2.5 mg/kg to induce anaesthesia in humans so the levels of propofol required 
to affect LTP is up to 25 fold more. However, the majority of this difference 
would be due to slow perfusion of propofol into brain slice tissue 34. Only 
1.9 mg/kg of propofol is needed for propofol-induced memory loss. Therefore, 





Sevoflurane (1,1,1,3,3,3-Hexafluoro-2-(fluoromethoxy)propane) is a vapour 
anaesthetic first approved for clinical use in Japan in 1990 35. Sevoflurane is 
used for both the induction and maintenance of general anaesthesia and is a 
highly fluorinated methyl isopropyl ether (Figure 5). It is a popular general 
anaesthetic due to its rapid onset and lack of airway irritation 36. Under 
anaesthesia, sevoflurane can reduce current times by up to 90%, effectively 
blocking the effect of GABA on its GABAA receptor 37. Sevoflurane has also 
shown to decrease the activity of glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) by up to 30%. GAPDH is an enzyme involved in the glycolysis 
pathway and is directly related to amount of glucose available for breakdown 
into energy. This reduction in activity prevents conformational changes in 




Figure 5: Chemical Structure of Sevoflurane  36. 
 
There has been increasing evidence that sevoflurane impedes memory 
processes due to the changing of gene expression in neurons in the 
hippocampus 10. This impairment can last for at least two days in young rats 
while up to 10 days in adult rats. Sevoflurane has been shown to up-regulate 
many different genes, for example, solute carrier family 6 protein (Slc6a3). This 
is a membrane bound transport protein that allows for the movement of solutes 
across the membrane, either through facilitated transport or coupling to the 
movement of another solute. Slc6a3 transports dopamine and it contributes to 
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different aspects of learning and memory processing. The upregulation of this 
protein in the hippocampus would cause an increase in the release of 
dopamine which may result in memory impairment. Acetylcholine receptor 
alpha-3 (Chrna3), a membrane receptor protein that binds the neurotransmitter 
acetylcholine and transports ions across the membrane is also shown to be up-
regulated 10. The upregulation of the Chrna3 may be the cause of the 
unconsciousness associated with sevoflurane.  
 
Sevoflurane has also been shown to down-regulate oxytocin neurophysin (OT) 
and arginine vasopression (Avp) which have both been implicated in learning 
and memory retention, and consolidation 10. Rat Insulin-like growth factor-1 
(IGF-1) has been shown to be down-regulated with sevoflurane 39. Insulin-like 
growth factor-1 is essential for normal growth and development of the brain, 
including cell proliferation, cell differentiation and cell survival. Insulin-like 
growth factor-1 mediates cell survival by preventing apoptosis. A reduction of 
the IGF-1 gene has the largest impact on the pyramidal cells of the 
cornu ammonis (CA) regions in the hippocampus. 
 
1.5 Genes of Interest 
 
The genes of interest were chosen based on a pilot study (Laura Bell, UoW; 
2014) which observed the differential expression of brain-derived neurotrophic 
factor (Bdnf) and activity-regulated cytoskeleton-associated protein (Arc) within 
the mouse brain in vivo after exposure to the two general anaesthetics, propofol 
and sevoflurane. 
 
1.5.1 Brain-Derived Neurotrophic Factor 
Bdnf is the most abundant and widely distributed neurotrophin in the 
mammalian CNS 40. The Bdnf gene is located on chromosome 2 in mice and 
consists of one coding exon at the start of the gene, followed by at least eight 
non-coding exons 40. In comparison, human BDNF gene is on chromosome 11. 
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Transcribed Bdnf mRNA always contains the first coding exon and one of the 
non-coding exons. The non-coding exon that is selected is determined by the 
tissue that Bdnf is being transcribed in. For example, exon II is only found in 
the brain while exon III is found in the brain, spleen and kidney 40. At least nine 
different promoters are found upstream of the gene, some of which are 
sensitive to changes in neuronal activity while others are regulated by 
hormones or epigenetics 41.  
 
Bdnf, just like other neurotrophins, plays a role in neuronal development in 
foetal humans and mice 42. Bdnf knockout mice developed with a reduction in 
CNS neurons and, most notably, had a marked reduction in peripheral neuronal 
development 43. This caused the majority of mice to die soon after birth 43. 
However, Bdnf does not just help the development of neurons in the foetus, it 
is also helps differentiate new neurons from neural stem cells and controls 
apoptosis of neurons 44. Bdnf is expressed in highest levels in the cortex, 
hippocampus and basal forebrain, which are all important in learning and 
memory 45.  
 
Bdnf binds to two known receptors, tropomyosin receptor kinase B (TrkB) and 
p75 neutrophin receptor (p75NTR) 46, 47. 5’ cap mRNAs and 5’ terminal 
oligopyrimidine (TOP) mRNAs are regulated by Bdnf through binding to TrkB 
and stimulating the phospoinositide 3-kinase (PI3-K) or extracellular 
signal-regulated kinases (ERK/MAPK) 48. Basal levels of Bdnf expression 
cause an increase in protein kinase B (Akt) activity which results in lowered 
caspase-9 and -3 activity and therefore increasing cell survival 47. However, 
general anaesthesia by isoflurane upregulates Bdnf in the cerebral cortex 
which decreases Akt activity, therefore increasing caspase-9 and -3 activity 





Figure 6: How Bdnf Influences Apoptosis.  A) Bdnf is expressed at a basal level and 
increases Akt activity via TrkB which reduces caspase-3 activity, therefore increasing cell 
survival. B) Bdnf levels are increased in the cerebral cortex due to isoflurane. However Akt 
activity is reduced from the p75NTR pathway which overrides the TrkB pathway resulting in 
high caspase-3 activity and cell apoptosis. 
 
Bdnf has been shown to induce activity dependent translation of 
dendritically-localised mRNAs, including Arc, which are essential in synaptic 
plasticity 49. Bdnf transcription is required for maintenance of late-phase LTP, 
therefore may be necessary for memory consolidation and recall 50. 
 
1.5.2 Activity-Regulated Cytoskeleton-Associated Pr otein 
Arc is an immediate early gene (IEG) that is rapidly expressed in neurons 
following a learning experience or induction of LTP through high-frequency 
stimulation (HFS) or Bdnf and has a role in altering synaptic strength 51, 52, 53. 
This gene is located on chromosome 8 in humans and chromosome 15 in mice. 
The Arc gene consists of three exons and two introns resulting in a 396 amino 
acid protein with a predicted weight of 55 kDa. 
 
Transcription of Arc occurs in response to synaptic activity through the synaptic 
activity-response element (SARE) which contains binding sites for cyclic AMP 
response element-binding protein (CREB) and a myocyte enhancer 
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factor 2 (Mef2) 54. The Arc promoter also contains multiple enhancer elements, 
three serum response elements (SRE) that bind serum response factor (SRF) 
which is recruited by synaptic activity or Bdnf 55, 56. There is a “Zeste-like” 
enhancer element that is also activated by synaptic activity or Bdnf 56. Within 
1 hour after transcription, Arc mRNA can be detected in dendrites up to 300 µm 
away 57. Transport to dendrites is accomplished through a heterogeneous 
nuclear ribonucleoprotein (hnRNP) binding to an 11 nucleotide response 
element within the coding region of Arc. Kinesin is used as a motor protein to 
move the Arc mRNA along microtubules to the recently activated dendrites 
where it is locally translated 58, 59. Arc mRNA contains exon junction complexes 
(EJC) that make it a target for nonsense-mediated decay (NMD), causing quick 
destabilisation of the mRNA. Also, Arc protein contains a proline, glutamic acid, 
serine, threonine (PEST) sequence that causes the protein to be quickly 
degraded by proteasomes, with an estimated half-life of 47 min 60. 
 
Arc antisense (AS) inhibited LTP consolidation but was reversed by F-actin 
stabilising drug, jasplakinolide. This strongly suggests that Arc’s function is in 
F-actin expansion and stabilisation 61. Long-term depression induced by 
dihydroxyphenylglycine (DHPG), a metabotropic glutamate receptor (mGluR) 
agonist, requires rapid translation of Arc. Inhibition of Arc translation shows a 
reduction in AMPA receptor endocytosis rates 62. Therefore Arc translation 
plays a role in both LTP and LTD 22. In Arc knockout mice early phase LTP is 
enhanced while late phase LTP is blocked 63. Also, disruption of Arc expression 
has led to the impairment in synaptic efficiency and memory consolidation 64. 





1.6 Real-Time Quantitative Polymerase Chain Reactio n 
 
Polymerase chain reaction (PCR) was first developed in 1983 by Kary Mullis, 
who was awarded the 1993 Nobel Prize in Chemistry for his contributions to 
the developments of methods within DNA-based chemistry 66. PCR uses a 
series of steps involving thermal cycling, dideoxynucleotides and DNA 
polymerase enzyme to amplify single copies of DNA to millions of copies. This 
is useful in situations where only part of a gene needs to be sequenced, and 
when only small amounts of a sample are available, such as a hair collected 
from a crime scene. PCR has three main steps of denaturation, annealing and 
elongation. During the denaturation step, the thermal cycler heats the samples 
up to 95 °C to disrupt the hydrogen bonds between the double stranded DNA. 
This results in single stranded DNA. The temperature is then lowered to 
50-65 °C for annealing, based on the temperature of the specific primers being 
used. The primers bind to their complementary recognition sequence on the 
single stranded DNA. After this the polymerase, usually Taq polymerase which 
was isolated from the thermophilic bacteria Thermus aquaticus, will bind to the 
primer-template DNA strand. In elongation the temperature is raised to 72 °C 
to synthesise a new DNA strand from the template strand 67, 68. 
 
Real-time PCR (qPCR) has a very similar method to PCR except it is able to 
quantify a targeted DNA molecule. This is achieved by using either (1) a 
non-specific fluorescent dye that binds with all double stranded DNA or (2) an 
oligonucleotide that is specific to part of the DNA sequence that is being 
amplified. This has a fluorescent reporter that fluoresces only after 
hybridisation with its complementary sequence. Quantification through qPCR 
is only a rough estimate as DNA integrity can be lower in some cases and 
higher in others, and enzyme efficiency may change. To improve the estimate, 
standardisation to reference genes is required. Reference genes are 
constitutive genes required by all cells for basic cellular function and survival. 
Commonly used standard genes are tubulin, which forms microtubules within 
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a cell and is present in all eukaryotic cells, or GAPDH 69. The minimum 
information for publication of quantitative real-time PCR experiments (MIQE) 
guidelines state a minimum of two reference genes is required for accurate 
quantitative analysis 68. 
 
1.7 Animal model for exposure trials  
 
The C57BL/6 strain of mouse, Mus musculus, was used. Mice are considered 
a good model organism to study human traits. Firstly, mice are small and easy 
to breed and maintain. For example, the cost of housing a mouse for an 
experiment is very low compared to other model organisms like non-human 
primates. A breeding pair can produce around 8-15 pups per litter, once each 
month. This timeframe allows for genetic inheritance analysis between 
generations. Secondly, the mouse genome has been completely sequenced 
and is approximately the same size as the human genome and contains about 
the same number of genes 70. In addition, the genome shows great synteny to 
the human genome. For most human genes, mice have a similar gene and 
mutations in these genes, often cause the same diseases. Knockout mice are 
available for many different genes 71. 
 
1.8 Hypothesis, Aims and Objectives 
 
1.8.1 Hypothesis 
It is hypothesised that there will be a change in gene expression of the 
memory-related genes, Bdnf and Arc, within the cerebral cortex of a mouse 
brain after a period of anaesthesia. 
 
1.8.2 Aims 
The aim of this research is to study the change in gene expression of Bdnf and 
Arc receptors in the cerebral cortex of the mouse brain after a period of 
anaesthesia from sevoflurane and propofol, using qPCR. This research has 
potential to help discover new anaesthetic drugs or learn more about 





Objective one is to study the expression of the genes of interest in mouse 
cortical tissue after t=4 hour period of anaesthesia from propofol and 
sevoflurane. Five mice will be used for each general anaesthetic where each 
mouse will have three brain slices used; one for treatment, one for t=0 hour 
control and one for t=4 hour control. This will be achieved through a range of 
molecular methodologies. Briefly, 
a) preparation of 400 µM mouse brain slices; 
b) period of anaesthesia; 
c) cortical tissue dissected from each slice; 
d) RNA extraction; 
e) DNAse treatment; 
f) cDNA synthesis; and 
g) qPCR. 
 
Objective two is to analyse the qPCR results to determine gene expression 
changes using the ∆∆CT method. 
 
Objective three is to confirm that the Bdnf protein is present in the cerebral 
cortex tissue of the mouse brain. This will involve immunohistochemistry (IHC) 
using commercial Bdnf antibodies. Briefly, 
a) preparation of OCT brain slice cryomolds; 
b) preparation of 10 µM sections using the Cryostat; 
c) staining with hematoxylin and eosin; 
d) incubation with primary antibodies and FITC secondary antibody; and 




Objective four is to confirm that the antibody is binding specifically to the Bdnf 
protein using western blotting. Briefly, this will involve: 
a) extraction of protein from mouse brain; 
b) running the protein extract on a SDS-PAGE gel; 
c) transfer of protein to a membrane; 
d) binding of primary and secondary antibody to the epitope on the 
membrane; and 






Materials and Methods 
 
The majority of these methods were carried out in the Molecular Genetics 
Laboratory (C.2.03) at the University of Waikato (UoW), Hamilton, New 
Zealand. The cryosectioning was performed in the Mammalian Physiology 
Laboratory (E.2.14), the microscopy work in the Microscopy Laboratory 
(R.2.29) and anaesthetic procedures in the Cortical Research Laboratory 
(C.1.14). Milli-Q water (mQH2O) purified at 15-18 MΩ·cm was used for all 
solutions and experiments. In addition, water used in RNA research was 
treated with 0.1% diethylpyrocarbonate (DEPC) to inactivate any RNase 
enzymes that may have been present. Glassware was autoclaved at 120 °C 
for 15 minutes and dried overnight in an 80 °C oven. Recipes for buffers and 
solutions used in this study can be found in Appendix 1. 
 
2.1 Statement on Animal Ethics 
 
The method for anaesthetising and euthanising all mice used in this research 
study was approved by the University of Waikato Animal Ethics Committee 
(protocol number 905, Appendix 2), and was in compliance with the standards 
provided in SOP Number: 9 (Appendix 3). 
 
2.2 Brain Tissue Experimentation 
 
To study the effects of anaesthetics on mouse neocortex in vitro, whole mouse 
brain was first extracted from a freshly euthanised mouse. For the anaesthetics 
to completely perfuse through the tissue the slices needed to be a maximum 
of 400 µm thick. For both propofol and sevoflurane there was a sample size of 
n=5 animals with t=0 hour control, t=4 hour control and t=4 hour treated slices 
taken from each mouse. 
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2.2.1 Dissection and Slicing of Brain Tissue 
Brain tissue was dissected from 10- to 15-week old C57BL/6 strain mice under 
carbon dioxide anaesthesia. After the whole brain was removed from the 
animal, it was immersed in a 100 mL beaker of carbogenated (95% oxygen, 
5% carbon dioxide) ice-cold “normal” artificial cerebrospinal fluid (nACSF) 
(125mM NaCl; 2.5 mM KCl; 1 mM MgCl2; 2 mM CaCl2; 1.25 mM NaH2PO4; 
26 mM NaHCO3 and 10 mM glucose). One to two millimetres of tissue was cut 
off the front and the rear of the brain with a scalpel blade to provide a flat 
surface to glue the brain onto a cutting block. The block was inserted into a 
vibratome (Campden Instruments, UK) and the tissue was sectioned in ice-cold 
nACSF into 400 µm thick coronal sections from front to back. Once a section 
was cut it was placed into carbogenated magnesium (Mg)-deficient ACSF 
(124 mM NaCl; 5 mM KCl; 2 mM CaCl2; 1.25 mM NaH2PO4; 26mM NaHCO3 
and 10 mM glucose). The brain slices were kept in the Mg-deficient ACSF at 
room temperature (RT) for two hours to activate seizure-like event (SLE) 
activity in the cortical tissue. Use of Mg-deficient ACSF is a widely used 
technique for generating SLE activity in cortical slices 72. 
 
2.2.2 Confirming Viability of Brain Sections 
Viability of the neocortical tissue was determined by use of an extracellular 
microelectrode (50 µm Teflon-coated tungsten) measuring local field potential 
(LFP) SLE activity. A section was placed into a perfusion bath (Kerr Tissue 
Recording System, Kerr Scientific Instruments, Christchurch, New Zealand) 
containing Mg-deficient ACSF perfused at a rate of 5 mL/min. The electrodes 
were sequentially placed into six different locations in the neocortex and 
spontaneous electrical activity measured (Figure 7). The signal was amplified 
(250x), band-pass filtered (high pass 1 Hz; low pass 100 Hz) and sampled at 
1000 Hz (PowerLab, ADInstruments, Sydney, Australia). The presence of 
Mg-deficient SLE activity (Figure 8) was used as an indication that the tissue 
was viable. In particular, the criterion that a minimum of 4 of 6 recorded 
locations showed SLE activity was used to include a slice in the study. This 
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was an arbitrary threshold based on the desire to use only those slices where 
the majority of the tissue could be shown to be viable. SLE activity was also 
used to infer the action of the anaesthetic on the brain slice as SLE activity is 
effectively blocked by volatile and non-volatile general anaesthetic drugs 72. 
Seizure-like event electrical activity was used to generate a box and whisker 




Figure 7: Electrical Impulse Recording Sites of Bra in Slice.  Brain slice showing the six 






Figure 8: Example of SLE Activity.  1) SLE activity over a short period of time. 2) 
Enlarged activity graph. 
 
2.2.3 Propofol Anaesthetic Procedure 
Propofol stock was prepared as a 1% solution of 2,6-di(propan-2-yl)phenol 
97+% (SAFC supply solutions, USA) in 20% Intralipid (Fresenius Kabi AB, 
Sweden). A final propofol concentration of 10 µg/mL was made by mixing 
0.2 mL of stock solution into 200 mL of Mg-deficient nACSF. After a viable 
section was identified, a net was placed on top of the slice to prevent flotation, 
remove surface tension and prevent the slice from drying out. The propofol 
solution was placed into a gravity fed drip system with the flow rate set to 
5 mL/min. SLE activity was recorded over the t= 4 hour treatment to observe 
the decline in SLE’s as the propofol took effect. Untreated control brain slices 
were kept in carbogenated nACSF for the duration of the anaesthetic exposure 
and then the neocortex was extracted for RNA. 
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2.2.4 Sevoflurane Anaesthetic Procedure 
With a viable slice prepared as described above in section 2.2.2, sevoflurane 
was delivered in carbogenated Mg-deficient ACSF using a syringe 
pump-driven system run at a flow rate of 5 mL/min. A final concentration 
equivalent to one minimum alveolar concentration (MAC) of sevoflurane was 
delivered to the brain tissue by adding 0.02 mL of liquid sevoflurane to 50 mL 
nACSF in the sealed syringe. The amount of sevoflurane required to reach 
one MAC using this method was determined by a previous study that showed 
through HPLC and headspace gas analysis that isoflurane reached one MAC 
when 0.01 mL was added to 50 mL nACSF in a syringe and pumped at 
5 mL/min 73. Sevoflurane is used at 2.1% in oxygen for anaesthesia while 
isoflurane is used at 1.1%. Therefore, sevoflurane is half as potent as 
isoflurane so the amount added to the nACSF was doubled from the isoflurane 
experiments to reach one MAC sevoflurane 5, 11. Similar to the propofol 
anaesthetic procedure, the SLE activity was recorded over the t=4 hour 
treatment to observe the decline in activity and ensure the sevoflurane was 
taking effect. Control slices were kept as described above in section 2.2.3. 
 
2.2.5 Neocortex Extraction 
A sterile scalpel was used to cut the neocortex away from the subcortical tissue 
in the slice. This tissue was placed into a sterile 2 mL screw cap tube containing 
1 mL of TRI Reagent® (Sigma-Aldrich, USA), a quarter of a cap of 0.1 mm 
zirconia/silica beads and one 2.5 mm glass bead. Immediately after extraction, 
the tissue samples were lysed using a FastPrep® FP120 (Thermo Scientific, 
USA) speed beater at a speed of 6.5 for 25 seconds at RT. This was repeated 
three times to ensure all the cells were completely lysed with a two minute 
interval between each cycle to prevent overheating of the machine and sample. 
The TRI Reagent® prevented the degradation of RNA and DNA. RNA was then 




2.3 RNA Extraction and Quantification 
 
RNA extraction was carried out on a dedicated bench for RNA work that had 
been decontaminated with RNase AWAY® (Invitrogen™, USA). These 
procedures minimise RNase contamination. All centrifugation was carried out 
in an Eppendorf 5424R centrifuge (Eppendorf, Germany) at 12,000 x g at 4 °C. 
The lysate containing glass beads was centrifuged for two minutes to collect 
the beads and cell debris at the bottom of the tube and the supernatant was 
transferred to a new 2 mL tube with 200 µL of chloroform for protein removal. 
After 15 seconds of vigorous shaking the samples were placed on a rotating 
wheel for 15 minutes at RT and then centrifuged for a further 15 minutes. The 
aqueous phase was transferred to a new 2 mL tube with 500 µL of isopropanol. 
The samples were allowed to stand at RT for 10 minutes to precipitate the RNA. 
The samples were centrifuged for eight minutes and the RNA formed a pellet 
on the side of the tube. The supernatant was removed from the tube and the 
pellet washed with 1 mL of 75% ethanol to remove salts. A final five minute 
centrifugation was done to ensure the RNA pellet was still on the side of the 
tube before removing the ethanol. After a brief air dry to remove the remaining 
ethanol, the RNA pellet was dissolved in 20 µL of 0.1% diethylpyrocarbonate 
(DEPC) treated water at 65 °C for 15 minutes and then cooled on ice for five 
minutes before quantification and storage. 
 
2.3.1 Quantity and Quality of RNA 
RNA quality and quantity was determined using a NanoDrop™ 2000 
Spectrophotometer (Thermo Scientific, UK). The NanoDrop measured the 
optical density at certain wavelengths (230 nm, 260 nm and 280 nm) to 
calculate the quantity and quality. An A260/A280 ratio of 1.8-2.0 is accepted as 
“pure” for RNA and an A260/A230 ratio of 2.0-2.2 for low phenol or guanidine 
contamination. RNA samples were stored at -80 °C to reduce RNA degradation 
over time. Each RNA sample was labelled according to its treatment (P, S), 
replicate number (1-5) and time point (0C, 4C, 4). 
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2.3.2 Native RNA Gel Electrophoresis 
RNA samples were run on a 1% native agarose gel to analyse the RNA integrity 
by viewing the ribosomal RNA bands (18S and 28S). To prepare the gel, 0.4 g 
of HyAgarose™ agarose (HydraGene, USA) was dissolved into 40 mL of 
1X TAE (40 mM Tris; 20 mM acetic acid; and 1 mM Ethylenediaminetetraacetic 
acid (EDTA)) buffer. This was conducted in a microwave and boiled until the 
solution was clear and free of agarose particles. After the agarose was 
completely dissolved and cooled to 60 °C, 1.5 µL of 10 mg/mL ethidium 
bromide (EtBr) was mixed into the solution. The gel was then poured into a 
level 8 cm x 7 cm gel mold and a comb was inserted. Once the gel had set, 
4 µL of RNA (200-400 ng/µl) was mixed with 1 µL of loading buffer and loaded 
onto the 1% agarose gel. Gel electrophoresis was electrophoresis at 45 V for 
one hour in 1X TAE buffer and the resulting gel was imaged on the Omega 
Lum G gel imager (Aplegen, USA). 
 
2.3.3 DNAse Treatment 
The RNA sample was DNAse-treated before the synthesis of complementary 
DNA (cDNA) in order to remove any genomic DNA contamination that was still 
present after RNA extraction. A 10 µL reaction was prepared in a 0.2 mL 
microcentrifuge tube which contained DNAse I enzyme (Zymo Research, 
USA), 1 µg of RNA sample, 10X DNAse Buffer and DEPC water (Table 1). This 
reaction was heated at 37 °C for one hour in a PTC-200 Peltier Thermocycler 
(Geneworks, Australia) to degrade DNA and then 1 µL of 500 mM EDTA was 
added to chelate Mg ions and heated at 65 °C for 10 minutes to inactivate the 






2.3.4 Complementary DNA Synthesis 
DNA polymerase used in PCR can only amplify up double stranded DNA 
(dsDNA); therefore, the mRNA samples must first be converted to cDNA. A 
20 µL reaction was prepared in a 0.2 mL microcentrifuge tube containing Tetro 
Reverse Transcriptase (Bioline, USA), RiboSafe RNase Inhibitor, 10 mM dNTP 
mix, 5X reverse transcriptase buffer, random hexamer primers, DNAse-treated 
RNA, and DEPC water (Table 2). Random hexamer primers were selected to 
provide uniform coverage rather than creating bias at the 3’ end using Oligo(dT) 
primers. A negative reverse transcriptase control was used where the reverse 
transcriptase was replaced with DEPC water. This was done to ensure the 
DNAse procedure worked and that there was no genomic DNA contamination 
in the sample following PCR. 
Table 1: DNAse Reaction Components.  Each reaction was made up in a 0.2 mL 
microcentrifuge tube. 
Component  Quantity ( µL) 
10X DNAse buffer 1 
RNA sample 1 - 8 (1 µg of total RNA) 
DEPC water Up to 10 µL 





 The samples were incubated in a PTC-200 Peltier Thermocycler (Geneworks, 
Australia) to carry out the reaction. The reaction program is outlined in Table 3. 
  
Table 2: cDNA Synthesis Reaction Components. Each 20 µL reaction was made up in a 
0.2 mL microcentrifuge tube 
Component  Concentration  Quantity ( µL) Final 
Concentration 
RNase inhibitor 10 U/µL 1 0.5 U 




5X 4 1X 
Random 
Hexamers 
40 µM 1 2 µM 
DNAse-treated 
RNA 
 1 N/A 
DEPC water  11 N/A 
Reverse 
transcriptase 
200 U/µL 1 10 U 
 
Table 3: cDNA Synthesis Program.  Synthesis of cDNA from RNA using these conditions. 
Cycle Temperature (°C) Time (min) 
Activation 25 10 
Reverse transcription 45 30 




2.4 PCR Sample Testing 
 
PCR was carried out to ensure the synthesised cDNA could be amplified with 
no evidence of genomic DNA contamination as this would skew the qPCR 
results. In the PCR hood, a master mix was prepared in a 1.5 mL 
microcentrifuge tube with HOT FIREPol® DNA polymerase (Solis BioDyne, 
Estonia). The master mix was then aliquoted out into 0.2 mL microcentrifuge 
tubes and cDNA added. The reaction mixture is outlined in Table 4 and 
standard PCR primers used in Table 5. 
 
Table 4: Reaction C omponents of PCR.  Each reaction was made up in a 0.2 mL 
microcentrifuge tube 
Component Concentration  Quantity ( µL) Final 
concentration 
B2 buffer 10X 2 1X 
MgCl2 25 mM 1.2 1.5 mM 
dNTPs 10 mM 0.4 200 µM 
Forward Primer 10 µM 0.5 0.25 µM 
Reverse Primer 10 µM 0.5 0.25 µM 
DEPC water  14.2 N/A 
cDNA  1 N/A 
HOT FIREPol® 
Polymerase 





Samples were amplified according to the program outlined in Table 6. 
Amplification was performed on a T100™ Thermal Cycler (BioRad, USA). For 
each PCR run there were two controls. Firstly a negative control to ensure the 
PCR components were free of DNA contamination. This negative control 
contained 1 µL of DEPC water instead of template cDNA. Secondly, reverse 
transcriptase negatives were used to ensure the cDNA was free of genomic 
DNA. 
Table 5: Six Primers U sed in Standard  PCR. Primer sequences used for standard PCR 
to test amplification of the cDNA samples. Two housekeeping genes were used, β2m and 
Gapdh. β2m primers amplified up an exon-exon boundary while Gapdh did not. Therefore 
Gapdh was used to verify no genomic DNA contamination. Bdnf was used to check the 
presence of a gene of interest. Genbank accession numbers are provided 74. 





































Table 6: PCR P rogram.  All end-point PCR reactions were done in 0.2 mL PCR 
microcentrifuge tubes and followed this program. 
Step Temperature 
(°C) 
Time Cycle  
Initial 
denaturation 
95 15 minutes 1x 
Denaturation 95 20 seconds 
30x Annealing 60 30 seconds 
Elongation 72 40 seconds 
Final elongation 72 5 minutes 1x 
 
 
Samples were run on 2% agarose gels stained with EtBr for band visualisation 
under UV light as outlined in section 2.3.2. Five microliters of PCR DNA Ladder 
(GenScript, USA) was run with the samples to estimate the size of the PCR 
products. 
 
2.5 Quantitative Polymerase Chain Reaction (qPCR) 
 
5X HOT FIREPol® EvaGreen® qPCR Mix Plus (Solis Biodyne, Estonia) was 
used for qPCR and the reactions were carried out according to the optimised 
program recommended by the manufacturer. A mastermix was made to obtain 
the final concentrations required for qPCR. These are outlined in Table 7. 
Table 7: qPCR Mastermix Components.  Mastermix was made up in a 1.5 mL 
microcentrifuge tube before being pipetted out into the 0.2 mL qPCR microcentrifuge tubes. 
qPCR Master Mix 
Components 
Concentration  Quantity ( µL) Final 
Concentration  
DEPC water  5 N/A 
Forward primer 10 µM 0.5 250 nM 
Forward primer 10 µM 0.5 250 nM 
5X HOT FIREPol® 
EveGreen® qPCR 
Mix Plus 





The cDNA samples were diluted 1:20 with DEPC water and, for each reaction, 
10 µL of cDNA was added. Adding 10 µL of cDNA for each reaction reduced 
the variation between the duplicates in the qPCR analysis. Each qPCR run 
contained all the t= 4 hour treatment and time-matched controls and was run 
with one primer at a time. The samples were run on a Rotor-Gene 6000™ 
Thermocycler (QIAGEN, Germany) using a 36 tube rotor disc. Every sample 
was run in duplicate with a negative control which contained no cDNA. A final 
melt curve was prepared to indicate how many qPCR products were present. 
One product should be present for each primer. The qPCR program is outlined 
in Table 8. 
Table 8: qPCR Program.  All qPCR reactions were done in 0.2 mL qPCR microcentrifuge 
tubes and followed this program which was optimised by Solis Biodyne. The samples were 
run on the Rotor-Gene 6000™ Thermocycler in the 36 well rotor disc. 
Step Temperature 
(°C) 
Time Cycles  
Initial 
denaturation 
95 12 minutes 1x 
Denaturation 95 15 seconds 
40x 
Annealing 65 30 seconds 
Elongation 72 30 seconds 
Final melt 80 10 seconds 
 
 
2.6 Statistical Analysis 
 
The Rotor-Gene™ 6000 software produces raw quantitative data which 
produces CT values based on a threshold set by a user. These CT values were 
applied to the ∆∆CT method. The ∆∆CT equation is outlined in Equation 1. The 
∆∆CT method compares the amplification of a specific primer in the treated 
sample and control sample. The fold changes generated from this comparison 
are then normalised to multiple housekeeping genes to give a normalised fold 
change of the genes of interest (GOI). Microsoft Office Excel (Microsoft, USA) 





Equation 1: ∆∆CT Method for qPCR Analysis. 
∆CT(treatment) = Gene of Interest Ct(treatment) – Reference gene Ct(treatment) 
∆CT(control) = Gene of Interest Ct(control) – Reference gene Ct(control) 
∆∆CT = ∆CT(treatment) - ∆CT(control) 
 
Quantitative PCR data shows the changes in mRNA expression levels; 
therefore, protein levels are also expected to change. Western blots and 
immunohistochemistry analysis was used to examine protein level changes. A 
two-tailed Student’s t-test was used to calculate a p-value that showed whether 
or not a result was of statistical significance. 
 
2.7 Organ Dissection and Protein Extraction 
 
Six organs (brain, heart, lung, kidney, spleen, and liver) were dissected from 
C57BL/6 strain mice between 10 and 15 weeks of age. The organs were 
washed with ice-cold 1X PBS (137 mM NaCl; 2.7 mM KCl; 10 mM Na2HPO4 
and 1.8 mM KH2PO4 at pH 7.4) and placed individually into 2 mL screw cap 
tubes containing one capful of 0.1 mm zirconia/silica beads, eight 2.5 mm glass 
beads and 500 µL of cell lysis buffer with protease inhibitor (Complete Mini 
Protease Inhibitor Cocktail Tablet (Roche, Germany)). The tissue samples 
were lysed using a FastPrep® FP120 (Thermo Scientific, USA) speed beater 
at a speed of 6.5 for 25 seconds at RT. This was repeated three times with a 
two minute interval between each cycle. The total cell lysates were then 
centrifuged for one minute at 12,000 x g to pellet cellular debris and glass 
beads. The supernatant was transferred to a new tube to remove the glass 
beads and cell debris. The cell lysate samples containing proteins were stored 




2.7.1 Bradford Assay on Cell Lysates 
The Bradford assay is an accurate procedure used to determine the 
concentration of protein in a solution. The Bradford dye is made up by mixing 
one part of Bio-Rad Protein Assay reagent (BioRad, USA) with four parts 
mQH2O and then filtering using Whatman® #1 filter paper. The Bradford dye 
was stored at 4 °C until used. A 10 mg/mL stock solution of bovine serum 
albumin (BSA) (Sigma-Aldrich, USA) was prepared and standards were diluted 
with 1X PBS as outlined in Table 9. The stock and working solutions were 
stored at -20 °C. 
 
Table 9: BSA Standards Concentrations. Concentrations of the BSA standards used in 
the Bradford Assay 
 Concentration of standard (mg/mL)  
 0 0.1 0.25 0.5 1 2 4 6 8 10 
10 mg/mL BSA 
(µL) 
0 1 2.5 5 10 20 40 60 80 100 
1X PBS (µL) 100 99 97.5 95 90 80 60 40 20 0 
 
 
A 96 well flat bottom, non-treated microplate (JET BIOFIL, China) was used for 
the assay and 100 µL of Bradford dye reagent was pipetted into each well of a 
row to be used followed by the addition of 1 µL of the appropriate BSA 
standard. The sample was mixed using a pipette tip. The organ cell lysates 
were diluted to 1:100 to bring the protein concentrations into the accurate 
readable range and then 1 µL was pipetted into wells separate to the standards 
that contain 100 µL of Bradford dye reagent. After a 5 minute RT incubation, 
the plate was inserted into a Multiskan™ GO Microplate spectrophotometer 
(Thermo Scientific, USA) and the 595 nm wavelength absorbance readings 
were recorded. Each standard and sample was performed in duplicate. A 
standard curve was produced and the absorbance values of the cell lysates 
were compared to this curve to calculate the protein concentrations of each 
organ tissue cell lysate.  
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2.8 Western Blot Analysis 
 
Western blot analysis was carried out to validate the antibody that was being 
used in immunohistochemistry as well as to assess the level of Bdnf protein 
within whole mouse brain extracts. 
 
2.8.1 SDS-PAGE Gel Electrophoresis 
As the anti-BDNF antibody recognises a 28 kDa Bdnf immature protein a 12% 
resolution sodium dodecyl sulphate polyacrylamide gel (SDS-PAGE) was 
chosen for the western blots. The gel was cast in a Mini-PROTEAN® 3 casting 
system (BioRad, USA). Milli-Q water was mixed with 3M Tris pH8.8, 10% SDS, 
37:1 (22%) Acrylamide:Bisacrylamide, 10% ammonium persulphate (APS) and 
tetramethylethylenediamine (TEMED) in the volumes outlined in Table 10. The 
stacking gel recipe is outlined in Table 11. 
 
Table 10: 12% Resolution SDS -PAGE Components.  Protein gels were made in a Mini-
Protean® III casting system. 




Milli-Q water  4485  
Tris pH8.8 3 M 2000 0.4 M 
37:1 
Acylamide:Bisacrylamide  
22% 8200 12% 
10% SDS 10% 150 0.1% 
10% APS 10% 150 0.1% 





Table 11: SDS-PAGE Stacking Gel. 




Milli-Q water  2985  
Tris pH6.8 0.5 M 1250 0.125 M 
37:1 
Acylamide:Bisacrylamide 
22% 660 2.9% 
SDS 10% 50 0.1% 
APS 10% 50 0.1% 
TEMED  5  
 
 
Once the gel had set it was loaded into Mini-Protean® III (BioRad, USA) gel 
electrophoresis tank with Tris-glycine SDS (25 mM Tris-Cl; 250 mM glycine and 
0.1% SDS) buffer. The organ cell lysates were mixed in a 1:1 ratio with 
2X sample loading buffer containing 2-mercaptoethanol and heated at 95 °C 
for 10 minutes in a Thermomixer® (Eppendorf, Germany) to denature the 
proteins. A 10 µL volume of each sample was loaded into different wells. A 
2.5 µL volume of PAGE-MASTER protein standard ladder (GenScript, USA) 
and 1.25 µL of WB-MASTER protein standard ladder (GenScript, USA) were 
also added to the gel. Electrophoresis was carried out at 140 V for 55 minutes 
at RT. 
 
2.8.2 Protein Transfer to PVDF Membrane 
Once gel electrophoresis had finished, the gels were removed from the plates 
and rinsed briefly in mQH2O. Hybond™-P polyvinylidene difluoride (PVDF) (GE 
Life Science, USA) membrane was cut to the appropriate size to cover the gel 
and then soaked in methanol for one minute followed by one minute in eBlot™ 
equilibrium buffer. The eBlot® system (GenScript, USA) was used to transfer 
the protein from the gel to the western blot membrane. The system was run for 
8 minutes to ensure all protein transferred. Ponceau S stain was used to 
determine if the protein transfer was successful. After observation of protein 
bands, the membrane was washed in TBS-T buffer (50 mM Tris-Cl; 




2.8.3 Incubation with Blocking Buffer and Antibodie s 
All steps during this protocol were conducted at RT with gentle agitation on an 
orbital mixer unless stated otherwise. Fresh 10% blocking buffer was made 
using milk powder (Alpine Diary Products, New Zealand) in 1X TBS (50 mM 
Tris-Cl; 150 mM NaCl at pH 7.5). The membrane was blocked for 1 hour using 
10% blocking buffer. Following this, the blocking buffer was removed and the 
membrane washed with 1X TBS-T for 5 minutes. A 1:100 concentration primary 
antibody solution was made by mixing 10 µL of primary antibody in 990 µL of 
10% blocking buffer. The membrane was sealed in a plastic bag with the 
primary antibody solution overnight at 4°C on an orbital shaker. Primary 
antibodies used in this research project are outlined in Table 12. 
Table 12: Primary and Secondary Antibodies  Used in  the Western Blot . 
Target Host Colonity Concentration  Manufacturer 
(Country) and 
Name 




Bdnf Rabbit Polyclonal 1:100 
Abcam (UK) 
ab72439 
Actβ Rabbit Polyclonal 1:1000 
Genetex (USA) 
GTX110564 

















The next day the primary antibody was removed and the membrane washed 
with 1X TBS-T three times for five minutes. A 1:10,000 concentration anti-rabbit 
horse radish peroxidase (HRP) secondary antibody (Abcam, UK) solution was 
diluted in 10% blocking buffer. The membrane was incubated in this secondary 
antibody solution for one hour. After incubation the antibody solution was 
removed and the membrane was washed with 1X TBS-T three times for 
15 minutes and a final wash for one hour. After the final wash, the washing 
buffer was removed and the membrane was developed with 0.1 mL/cm2 
WesternBright™ Sirius™ HRP developing solution (Advansta, USA). This 
developing reaction was incubated for five minutes in the dark before being 
imaged on the Omega Lum G gel imager (Aplegen, USA). 
 
2.9 Immunohistochemistry and Microscopy 
 
Hematoxylin and Eosin (H&E) staining procedure was carried out to ensure 
cells were intact for IHC and to have a reference to navigate the IHC sections. 
Immunohistochemistry was used to verify that Bdnf was expressed in the 
neocortex and to compare the level of expression to other regions of the brain 
such as the hippocampus. Frozen brain tissue was sectioned using a cryostat 
in preparation for H&E and IHC. 
 
2.9.1 Cryosectioning of Brain Slices 
Active brain slices were placed into cryosection molds and covered with FSC 
22™ Frozen Section Compound (OCT) (Lecia, Germany) then flash frozen with 
Frostbite® (Lecia, Germany) spray. The frozen brain slice molds were wrapped 
in tin foil and kept at -80 °C overnight to ensure they were completely frozen. 
The Lecia CM1850 UV cryostat machine (Lecia, Germany) chamber was kept 
at -35 °C during cryosectioning as this temperature produced the best sections. 
Sections (10 µm) were cut using a Surgipath DB80 LX Premium Low Profile 
disposable blade (Lecia, Germany) and placed onto Polysine™ microscope 
slides (LBSP4981) (Thermo Scientific, USA) which were kept in a slide box at 
-80 °C until used. 
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2.9.2 Hematoxylin and Eosin Staining 
All steps during this protocol and the IHC protocol were done at RT unless 
stated otherwise. Slides containing brain sections were defrosted for five 
minutes before surrounding the sections with Liquid Blocker (Super Pap Pen) 
(Daido Sangyo, Japan) to reduce the amount of H&E used. After the pap pen 
had dried, the slides were fixed in 4% paraformaldehyde (PFA) for five minutes 
and then washed with running tap water for one minute to remove excess 
formaldehyde. Surgipath® Harris Hematoxylin (Lecia, Germany) stain was 
pipetted onto the slides, on a horizontal staining tray, and left for five minutes 
to stain the nuclei and then washed in water to remove excess stain. Scott’s 
tap water was used as blueing reagent to help hematoxylin blue the nuclear 
chromatin and nuclear membranes. The slides were then rinsed with Scott’s 
tap water for two minutes. Surgipath® Eosin (Alcoholic) (Lecia, Germany) was 
pipetted onto the slides and left for ten minutes to stain red the negatively 
charged proteins in the cytoplasm. The slides were washed with running water 
three times for three minutes each time and then dried and mounted with 
Shandon™ Immu-Mount™ (Thermo Scientific, USA). The dry slides were then 




Slides containing brain sections were defrosted for five minutes before fixing in 
chilled 4% PFA for 10 minutes and then washed three times for five minutes 
each time in 1X PBS (137 mM NaCl; 2.7 mM KCl; 10 mM Na2HPO4 and 
1.8 mM KH2PO4 at pH 7.4). The slides were soaked in 0.5% Triton X-100 for 
30 minutes to permeate the cell membranes and then washed three times for 
five minutes each time in 1X PBS. Slides were soaked in 0.9% H2O2 to block 
endogenous peroxidases and washed two times for five minutes each time in 
1X PBS and one time in 1X PBS-T (137 mM NaCl; 2.7 mM KCl; 
10 mM Na2HPO4; 1.8 mM KH2PO4 and 0.2% Tween-20 at pH 7.4) for five 
minutes. The sections were encircled with Super Pap Pen and left to dry for 
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two minutes before being washed in 1X PBS. The sections were blocked with 
5% goat serum in 0.3 M glycine and washed with 1X PBS for five minutes 
before pipetting a 1:200 concentration primary antibody solution, which was 
made by mixing 5 µL of primary antibody in 995 µL of 5% goat serum with 0.3 M 
Glycine. Glycine was used to quench any unreacted aldehydes therefore 
reducing background noise. The primary antibody incubated overnight in a 
humidity box at 4 °C and then washed two times for five minutes each time in 
1X PBS and one time in 1X PBS-T for five minutes to remove excess primary 
antibody. A 1:2000 concentration secondary antibody solution was made using 
1 µL of secondary antibody in 1,999 µL of 1X PBS. The secondary antibody 
was pipetted onto the slides and left for 30 minutes in the dark. Primary and 
secondary antibodies are outlined in Table 13. A final wash of two times for five 
minutes each time in 1X PBS and one time in 1X PBS-T for five minutes was 
done, to remove excess secondary antibody and reduce background, before 
drying the slides and mounting with coverslips using Fluoroshield™ with DAPI 
(4’, 6-diamidino-2-phenylindole) (Sigma-Aldrich, USA). DAPI binds to adenine 
and thymine rich regions in DNA and is used to stain the nucleus. The 
fluorescent slides were viewed using an Axiostar plus transmitted light 
microscope (Carl Zeiss, Germany). Alexa Fluor ® 488 secondary antibody was 
excited under 495 nm wavelength light. 
Table 13: Primary and Secondary Antibodies  Used in IHC.  
Target  Host  Colonity  Concentration  Manufacturer 
(Country) and 
Name 
























This chapter outlines the results from the molecular methodologies used to 
extract RNA from the mouse cortical brain tissue and convert it to a cDNA 
template, which was subsequently used to analyse gene expression during a 
four hour anaesthetic drug exposure. The protein data from the western blots 
and immunohistochemistry on coronal brain slices is also included in this 
chapter. 
 
3.1 In Vitro Anaesthetic Exposure Using a Mouse Model 
 
Adult male and female wildtype C57BL/6 mice between 10 and 15 weeks old 
were involved in this study. After the cortical tissue was confirmed to contain 
electrical activity, control slices were kept in nACSF and treatment slices were 
exposed to either propofol or sevoflurane. 
 
3.2 Brain SLE Activity 
 
Seizure-like events were recorded as a way of identifying brain slices that 
pertained to our criteria of a viable brain slice. This meant that four of the six 
recorded locations showed SLE activity (Figure 7). This data shows the SLE 
frequency and amplitudes which were averaged out across all active locations 
within a slice and a box and whisker plot generated from these averages for 





Figure 9: SLE Frequency for Propofol and Sevofluran e. SLE frequency is similar 
between propofol and sevoflurane, however propofol did have a much lower minimum 




Figure 10: SLE for Propofol and Sevoflurane.  SLE amplitude for sevoflurane is increased 
compared to propofol. The average amplitude for propofol was 44.55 µV while sevoflurane 












































3.3 RNA Quantification and Qualification 
 
Following confirmation of active electrical recordings, RNA was extracted from 
the brain slice and the quality and quantity was analysed using a NanoDrop™ 
2000 Spectrophotometer. The quantity was assessed so approximately the 
same amount of RNA template would be used for downstream applications. 
 
3.3.1 NanoDrop Analysis of Propofol RNA Samples 
Fourteen of the extracted RNA samples had a NanoDrop reading consistent 
with pure RNA, except for P5T4C. The RNA concentrations ranged from 
193-440 ng/µL (Table 14). 
Table 14: Mice Used in the Propofol Treatment E xperiment.  Mice were aged between 
10 and 15 weeks old. Both female and male mice were used. Each RNA sample was labelled 
according to its treatment (P, S), replicate number (1-5) and time point (0C, 4C, 4). 




P1T4C 347.9 1.92 




P2T4C 391.3 1.85 




P3T4C 226.1 1.88 




P4T4C 291.5 1.84 




P5T4C 193.7 1.73 





3.3.2 NanoDrop Analysis of Sevoflurane RNA Samples 
All 15 sevoflurane treated and control RNA samples had A260/A280 ratios that 
would be considered pure. The sevoflurane RNA concentrations ranged from 
164.1-350.4 ng/µL. Compared to the propofol samples, the sevoflurane 
samples had a lower average concentration. S5T0C had a RNA concentration 
that was lower than the rest which could have been from not removing enough 
of the aqueous layer during TRI Reagent® RNA extraction or from the RNA 
pellet drying out and not dissolving into mQH2O (Table 15). 
Table 15: Mice Used in the S evoflurane Treatment Experiment.  Mice were aged between 
10 and 14 weeks old. Both female and male mice were used. Each RNA sample was labelled 
according to its treatment (P, S), replicate number (1-5) and time point (0C, 4C, 4). 




S1T4C 350.4 1.93 




S2T4C 226.8 1.91 




S3T4C 251.2 1.86 




S4T4C 275.7 1.92 




S5T4C 253.6 1.92 





3.3.3 Non-Denaturing Gel Electrophoresis Analysis o f 18S and 28S rRNA 
for Propofol 
To quickly check the integrity of the RNA, two samples were run on a 1% native 
TAE agarose gel; the original 2000 ng extracted RNA, and 200 ng of 
DNAse-treated RNA (Figure 11). 
 
 
Figure 11: Non-Denaturing Agarose Gel Testing rRNA Integrity. Non-denaturing 1% 
TAE agarose gel electrophoresis at 45 V for one hour. 1) 2000 ng untreated RNA sample 2) 
200 ng DNAse-treated RNA sample. The rRNA bands are not distinguishable and have 
smeared across the gel. This indicates the RNA has been degraded. A ladder was not 
included with this experiment. 
 
Figure 11 shows observation of a smear with a bright band in Lane 1. In 
comparison, the DNAse-treated sample had a lower concentration of RNA so 
the smear did not show up as clearly as the untreated sample. However, there 
was no clear indication of rRNA bands. Because the brain tissue was placed 
directly into Tri Reagent® and extracted immediately, the most likely cause of 
degradation was the quality of the water used to dissolve the extracted RNA. 
 
To overcome this issue, mQH2O was treated with 0.1% DEPC followed by 
sterilisation by autoclaving, and then another RNA sample was extracted from 
a mouse cortical brain tissue. The sample was then run on a 1% TAE agarose 
and two distinct bands were present, marking the 18S and 28S rRNA. 
Therefore, our data demonstrates that the RNA was mostly free of degradation 





Figure 12: Second rRNA Integrity Test.  Non-denaturing 1% TAE agarose gel 
electrophoresis at 45 V for one hour. 1) 1000 ng of RNA sample after the water had been 
DEPC-treated and RNA had been DNAse-treated. GenScript® PCR DNA Ladder is 
included. Both the 18S and 28S rRNA bands are visible in this RNA sample. This indicates 
that the RNA has not been degraded. 
 
Only the zero hour control (t=0) propofol RNA samples were run on a 1% TAE 
agarose gel to check for degradation due to these samples not being used for 
qPCR analysis. This was done to minimise the loss of RNA from the samples 
that were going to be used for qPCR analysis because of low extracted RNA 
quantity. The zero hour control propofol RNA samples are shown in Figure 13. 
 
 
Figure 13: rRNA Bands of the Five t=0 Hour Control Propofol Samples. Non-denaturing 
1% TAE agarose gel electrophoresis at 45 V for one hour. 1) P1T0C 2) P2T0C 3) P3T0C 4) 
P4T0C 5) P5T0C. GenScript® PCR DNA Ladder is included. 
 
Both the 18S and 28S rRNA bands can be seen. The 28S band is roughly twice 
the intensity of the 18S band which indicates good quality RNA. 
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3.3.4 Non-Denaturing Gel Electrophoresis Analysis o f 28s and 18s rRNA 
for Sevoflurane 
As with the propofol samples only the zero hour control sevoflurane RNA 
samples were run to minimise loss of the RNA samples that were going to be 
used in qPCR analysis. The zero hour control sevoflurane RNA samples are 




Figure 14: rRNA Bands of the Five t=0 Hour Control Sevoflurane Samples. Non-
denaturing 1% TAE agarose gel electrophoresis at 45 V for one hour. 1) S1T0C 2) S2T0C 
3) S3T0C 4) S4T0C 5) S5T0C. GenScript® PCR DNA Ladder is included. 
 
All 28S and 18S rRNA bands can be seen. However, the 28S bands are faint 





3.4 Standard PCR to Ensure No Genomic DNA Contamina tion 
 
After cDNA synthesis, standard PCR was used to determine if any genomic 
DNA contamination was present in the RNA sample and optimize cycling 
conditions if necessary. For each sample the -RT control from the cDNA 
synthesis was tested with the Gapdh primer. The Gapdh primers produce an 
87 bp product but they do not span an exon-exon boundary. As a result, 
genomic DNA will be amplified if it is present. Thus, the –RT control is expected 
to contain no cDNA because no reverse transcriptase was included during 
cDNA synthesis. Alongside the -RT control was the cDNA sample amplified 
with Gapdh, Bdnf1 (103 bp), Bdnf2 (206 bp) or β2m (104 bp) primers. The β2m 
primer is an exon boundary spanning primer which would only amplify cDNA 
and so it was used as a positive control to ensure cDNA synthesis occurred 




3.4.1 Propofol Samples 
DNAse-treatment occurred at 37 °C for 15 minutes. After this the 
DNAse-treated RNA was converted to cDNA and run through a standard PCR 
test. The agarose gel electrophoresis results from the five P1 amplified 
samples are shown in Figure 15. 
 
 
Figure 15: Standard PCR on 15 Minute DNAse-Treated Propofol Samples. This 2% 
agarose gel contains the P1 cDNA sample set and two test samples and was run at 90 V for 
30 minutes. 1) P1T0C -RT control with Gapdh primers. 2) P1T0C cDNA with Gapdh primers. 
3) P1T0C cDNA with Bdnf2 primers. 4) P1T0C cDNA with Bdnf primers. 5) P1T4C -RT 
control with Gapdh primers. 6) P1T4C cDNA with Gapdh primers. 7) P1T4C cDNA with 
Bdnf2 primers. 8) P1T4C cDNA with Bdnf primers. 9) P1T4 -RT control with Gapdh primers. 
10) P1T4 cDNA with Gapdh primers. 11) P1T4 cDNA with Bdnf2 primers. 12) P1T4 cDNA 
with Bdnf primers. Wells 13 to 20 are protocol test samples. Well 21 is the PCR negative. 
GenScript® PCR DNA Ladder is included on left-hand side. There is contamination in every 




The agarose gel showed that there was a band in all the -RT controls and no 
band present in the PCR negative. This suggested there was genomic DNA 
contamination in these samples and the DNAse treatment had failed. DNAse 
treatment was then performed at 37 °C for 30 minutes to optimise genomic 
DNA removal. The results of the P1 samples with the 30 minute treatment are 
shown in Figure 16. 
 
 
Figure 16: Standard PCR on 30 Minute DNAse-Treated Propofol Samples. 2% TAE 
agarose gel electrophoresis at 90 V for 30 minutes. This gel contains the P1 cDNA sample 
set. 1) P1T0C -RT control with Gapdh primers. 2) P1T0C cDNA with Gapdh primers. 3) 
P1T0C cDNA with β2m primers. 4) P1T0C cDNA with Bdnf primers. 5) P1T4C -RT control 
with Gapdh primers. 6) P1T4C cDNA with Gapdh primers. 7) P1T4C cDNA with β2m 
primers. 8) P1T4C cDNA with Bdnf primers. 9) P1T4 -RT control with Gapdh primers. 
10) P1T cDNA with Gapdh primers. 11) P1T cDNA with β2m primers. 12) P1T cDNA with 
Bdnf primers. 13) PCR negative. GenScript® PCR DNA Ladder is included on left-hand side. 





Again there was still observation of genomic DNA contamination in the -RT 
controls. The DNAse treatment time was further increased to one hour. The 
results from the P1 samples are shown in Figure 17. 
 
 
Figure 17: Standard PCR on 60 minute DNAse-Treated Propofol Samples. 2% TAE 
agarose gel electrophoresis at 90 V for 30 minutes. This gel contains the P1 cDNA sample 
set. 1) PCR negative. 2) P1T0C -RT control with Gapdh primers. 3) P1T0C cDNA with 
Gapdh primers. 4) P1T0C cDNA with β2m primers. 5) P1T0C cDNA with Bdnf primers. 
6) P1T4C -RT control with Gapdh primers. 7) P1T4C cDNA with Gapdh primers. 8) P1T4C 
cDNA with β2m primers. 9) P1T4C cDNA with Bdnf primers. 10) P1T4 -RT control with 
Gapdh primers. 11) P1T4 cDNA with Gapdh primers. 12) P1T4 cDNA with β2m primers. 13) 
P1T4 cDNA with Bdnf primers. GenScript® PCR DNA Ladder is included on left-hand side. 
This gel shows there is no genomic DNA contamination within the samples. 
 
The one hour DNAse treatment removed genomic DNA completely from the 
RNA samples. The β2m and Bdnf still amplified the expected product size so 
the long DNAse treatment time did not degrade the mRNA. This PCR protocol 
was repeated for all five propofol animal sample sets which included the 




3.4.2 Sevoflurane Samples 
The one hour DNAse treatment protocol consistently removed all genomic DNA 
from the sevoflurane samples as shown in Figure 18. 
 
 
Figure 18: Standard PCR on Sevoflurane Samples.  2% TAE agarose gel electrophoresis 
at 90 V for 30 minutes. This gel contains the S1 cDNA sample set. 1) PCR negative. 
2) S1T0C -RT control with Gapdh primers. 3) S1T0C cDNA with Gapdh primers. 4) S1T0C 
cDNA with β2m primers. 5) S1T0C cDNA with Bdnf primers. 6) S1T4C -RT control with 
Gapdh primers. 7) S1T4C cDNA with Gapdh primers. 8) S1T4C cDNA with β2m primers. 
9) S1T4C cDNA with Bdnf primers. 10) S1T4 -RT control with Gapdh primers. 11) S1T4 
cDNA with Gapdh primers. 12) S1T4 cDNA with β2m primers. 13) S1T4C cDNA with Bdnf 
primers. GenScript® PCR DNA Ladder is included on left-hand side. This gel shows there 
is no genomic DNA contamination within the samples. 
 
A band was observed above the primer dimer in the PCR negative which 
indicated contamination. However, no contamination was seen in any of the 
three –RT controls therefore it was assumed that this was contamination from 




3.5 Quantitative PCR Analysis 
 
Quantitative PCR analysis was carried out on the t=4 hour control and t=4 hour 
treated samples for both propofol and sevoflurane. Bdnf and Arc were the 
genes of interest analysed. Reference genes were used as internal controls to 
normalise the qPCR results. The MIQE guidelines recommends the use of at 
least two reference genes 68. Four reference genes were used in this qPCR 
analysis; Gapdh, β2m, Actβ and HPRT1 since they have been used in previous 
published studies 69, 79, 80. The nucleotide sequence of the six genes used in 
this study was previously confirmed by cloning the PCR fragments and Sanger 




3.5.1 Testing Sample Concentrations for qPCR Analys is 
There was very little sample to work with in qPCR so diluting the cDNA samples 
was the only way to ensure enough volume to complete the qPCR analysis. A 
test qPCR was run using an undiluted sample and one that had been 
diluted 1/5. β2m was amplified and the take-off value used to determine the 
best dilution to use. If the take-off value was greater than 30 cycles for each 
sample at the 1/5 dilution then the samples were only diluted by 1/2. The 
amplification curve for the propofol samples is shown in Figure 19. 
 
 
Figure 19: Propofol Sample Concentration Test.  The blue lines are propofol samples that 





P5T4 with a 1/5 dilution was an outlier having a take-off value of 31.5. P3T4 
with a 1/5 dilution failed to amplify but the undiluted sample had a take-off value 
of 20.9 which is in line with the other undiluted samples so it was assumed that 
this was due to a loading error and not a sample error. The majority of 1/5 
diluted propofol samples have a take-off value lower than 30 cycles so the 
propofol samples were diluted 1/5. This test was repeated for sevoflurane and 
the amplification curve for the sevoflurane samples is shown in Figure 20. 
 
 
Figure 20: Sevoflurane Sample Concentration Test.  The blue lines are propofol samples 
that have not been diluted. The red lines are the same samples with a 1/5 dilution. 
 
P1T4C undiluted had a take-off value of 31.7 and P1T4C 1/5 dilution had a 
take-off value of 33.1. This sample was kept undiluted for gene expression 
analysis. As with the propofol samples, the majority of 1/5 diluted sevoflurane 
samples have a take-off lower than 30 cycles so the sevoflurane samples were 





3.5.2 Amplification and Melting Point Curves 
Each qPCR run contained only one primer set and all samples of either the 
propofol or sevoflurane sample sets. This was done to remove the run to run 
variation within each sample set and allow more accurate analysis. Each run 
had all samples run in duplicates to give more accurate results, and had a no 
template control which contained the PCR master mix and primer. An example 
of the amplification graph produced from a qPCR run is shown in Figure 21. All 
amplification curves are included in Appendix 4. 
 
 
Figure 21: Amplification Curve of Arc. Each sample is run in duplicate with only one 
primer per qPCR run. There are 10 different samples on this curve. Each sample was run in 
duplicate. 
 
Melt curves were carried out on each qPCR run to analyse the product(s). This 
ensured that each sample had the same product and that each negative did 
not contain the same product as the samples, if there was amplification. The 
temperature at which an amplification product denatures depends on the size 
of the product and the G-C content. If a melt curve showed that there was the 
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same product in both the negative and the samples, then this would be 
considered as contamination and the run would be repeated. The melt curve 
for Arc is shown in Figure 22. 
 
 
Figure 22: Melting Curve of Arc. The peak corresponds to an amplified product from the 
qPCR run. This melting curve only has one product in all samples and no product in the 
negative. There are 10 different samples on this curve. Each sample was run in duplicate. 
 
3.6 Statistical Analysis of qPCR Amplification Data  
 
Gene expression analysis for both the in vitro propofol and sevoflurane treated 
mouse brain cortical samples was normalised to the four reference genes. The 
t=4 hour controls were given a fold change of 1 to compare to the treated 
samples. There was a sample size of n=5 and the t=4 hour treatment was 
compared to the t=4 hour control. However, for both Bdnf and Arc there was 
one sample that did not amplify enough to pass the threshold and so the 
analysis only included a sample size of n=4. The ∆∆Ct of qPCR analysis was 
used (Equation 1) and the data is based on the controls having a regular 
expression of 1. 
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3.6.1 Gene Expression Results for Propofol 
Following qPCR and statistical analysis, Figure 23 shows that Bdnf was 
downregulated by a fold change of 0.710 and Arc was upregulated by a fold 
change of 1.560. Table 16 contains the p-values generated by a two-tail 
Student’s t-test. Arc mRNA transcripts were 11 times more abundant than Bdnf 
mRNA transcripts in the control samples. This was increased to 24 times more 
Arc in the treated sample as shown by Figure 24. Raw data can be found in 
Appendix 4 
Table 16: Gene Expression Results for Propofol. P-value is calculated from a two-tailed 
Student’s t-test. 
 Bdnf Arc 
Fold Change Average  0.710 1.560 
Standard Error  0.147 0.401 





Figure 23: qPCR Gene Expression Analysis of Propofo l. Bdnf is downregulated while 





















Figure 24: Relative Expression of Bdnf and Arc for Propofol. Arc mRNA transcript 
quantity within the control samples are roughly ten times the amount compared to Bdnf. 
 
3.6.2 Gene Expression Results for Sevoflurane 
Figure 25 shows Bdnf was upregulated by a fold change of 1.859. Arc was 
downregulated by a fold change of 0.348 which was statistically significant with 
a p-value of 0.003. Table 17 contains the p-values generated by a two-tail 
Student’s t-test. Arc mRNA transcripts were 37 times more abundant than Bdnf 
mRNA transcripts in the control samples. This was decreased to 9 times more 
Arc in the treated sample as shown by Figure 26. Raw data can be found in 
Appendix 4. 
Table 17: Gene Expression Results for Sevoflurane.  P-value is calculated from a 
two-tailed Student’s t-test. 
 Bdnf Arc 
Fold Change Average  1.859 0.348 
Standard Error  0.363 0.034 





























Figure 25: qPCR Gene Expression Analysis of Sevoflu rane.  Bdnf is upregulated while 




Figure 26: Relative Expression of Bdnf and Arc for Sevoflurane.  As the same with 
Propofol, Arc mRNA transcript quantity within the control samples are roughly ten times the 
amount compared to Bdnf. This changes to be roughly five times the amount in the 











































3.7 Bradford Assay 
 
Bradford assay was carried out to ascertain the protein concentration of the six 
whole mouse organ extracts. Protein standards were plated out and graphed 
to produce a standard curve which the absorbance values of the organ extracts 
were compared against. The standard curve is shown in Figure 27. 
 
 
Figure 27: Protein Standard Curve from the Bradford  Assay.  Protein standards started 
at a concentration of 0 mg/mL and went to 0.5 mg/mL. The line of best fit gave an equation 
of y = 0.5872x + 0.1273 with an R-value of 0.9939. 
 
Only up to the 0.5 mg/mL standard was used to produce a line of best fit as 
past this value the graph started to plateau. Whole organ extracts were diluted 
by 1:100 to bring the absorbance readings into the accurate readable range. 
These values and the final protein concentrations are shown in Table 18. A 
protein range of 4 – 21 mg/mL was extracted. Thus, sufficient concentrations 
for western blot analysis. Coomassie results indicated protein was not 
degraded and distinct bands were seen between 10 – 120 kDa (data not 
shown). 





















Bradford Assay Protein Standard Curve
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Table 18: Absorbance Values and Concentrations of Mouse Organ Extracts.  Large 
concentrations from the Heart and Lung may have been from left over blood within the 
tissue. 
Organ Absorbance Concentration (mg/mL) 
Liver 0.1536 4.4789 
Spleen 0.1548 4.6747 
Kidney 0.1631 6.0967 
Brain 0.1780 8.6257 
Lung 0.2055 13.3174 





3.8 Western Blot 
 
Quantitative PCR data suggests that Bdnf mRNA levels change after exposure 
to propofol or sevoflurane. As a change in mRNA quantity doesn’t always 
correlate to a change in protein levels, protein analysis was carried out. 
Western blots and IHC were carried out concurrently due to the time constraints 
of this study. Western blots were performed to verify that the Bdnf protein was 
present within the mouse brain and to validate the commercial antibody that 
would be used for IHC. The Bdnf antibody N-20 from Santa Cruz Biotech was 
selected due to the high citation count and positive reviews. The predicted 
molecular weight of the Bdnf precursor protein is 32 kDa and 14 kDa for the 
mature protein. However, the western blot produced a band at roughly 55 kDa 
as shown in Figure 28. 
 
 
Figure 28: Santa Cruz Biotech Bdnf N-20 Antibody We stern Blot on Whole Mouse 
Brain Extract.  12% SDS-PAGE electrophoresis at 140 V for 50 minutes. 50 µg of protein 
was loaded. There is one band present at 55 kDa. This band may be an off target binding 






As the Bdnf N-20 antibody is a polyclonal antibody, the band could have come 
from either off target binding or polymer combinations of the precursor and 
mature protein. A Beta-actin positive control was run on brain extract at three 
different concentrations to ensure the protocol was working correctly. A band 




Figure 29: Genetex Beta-actin GTX110564 Antibody We stern Blot on Whole Mouse 
Brain Extract.  12% SDS-PAGE electrophoresis at 140 V for 50 minutes. 1) 50 µg protein 
loaded. 2) 12.5 µg protein loaded. 3) 5 µg protein loaded. Genscript WB-MASTER protein 





The Laemmli buffer used to denature and reduced the sample during the 
boiling step only had a 10% β-mercaptoethanol concentration so to rule out the 
formation of protein polymers this concentration was increased to 25%. The 
primary antibody concentration was increased from 1:1,000 to 1:100 and a 
protein concentration gradient was also included to ensure the protein 
concentration was high enough to show the 14 kDa and 32 kDa proteins. The 
western blot showed a band at 55 kDa again with no bands at 14 kDa or 32 kDa 
as shown in Figure 30. 
 
 
Figure 30: Santa Cruz Biotech Bdnf N-20 Western Blo t with Higher Protein 
Concentration of Mouse Whole Brain Extract.  12% SDS-PAGE electrophoresis at 140 V 
for 50 minutes. Protein loading quantity: 1) 100 µg 2) 50 µg 3) 25 µg 4) 10 µg 5) 5 µg 6) 2 µg. 





The conclusion from this set of western blots was that the Santa Cruz Bdnf 
N-20 antibody we received was defective so the Abcam ab72439 Bdnf antibody 
was ordered. The predicted size of the ab72439 antibody is 28 kDa. This 
western blot was run with whole extract from mouse brain, kidney and heart. A 
band was observed at 28 kDa as shown in Figure 31. Extra bands were 
observed at 52 kDa in the kidney sample which could be protein polymers or 
off target binding to other neurotrophic factors. This western blot was replicated 




Figure 31: Abcam Bdnf ab72439 Antibody Western Blot . 4%-16% SDS-PAGE 
electrophoresis at 150 V for 50 minutes. 1) Mouse whole brain extract. 2) Mouse whole 
kidney extract. 3) Mouse whole heart extract. Each extract had a protein concentration of 






Figure 32: Ponceau S Stain of Membrane.  The three lanes show protein transfer onto the 
membrane was successful. PAGE-MASTER GenScript ladder is included. 
 
In the brain extract there is a band at 28 kDa as predicted but a range of high 
molecular weight bands including a band at 68 kDa which could be a polymer 
or off target binding. There is a group of bands at 50 kDa in the kidney extract 
which could be protein polymers and a slight band at 28 kDa in the heart 




3.9 Hematoxylin and Eosin Staining 
 
H&E was carried out to ensure the cells of the IHC sections were still viable for 
IHC and to have a reference to navigate the IHC sections. The neocortex is 
dense in nuclei which is shown by the violet colour from the hematoxylin stain 




Figure 33: H&E Staining of a Mouse Brain Coronal Cr yosection.  Tissue is from a female 
mouse aged 10 weeks and section in OCT. The cells of the section are still viable as shown 
by the hematoxylin staining the nuclei of the neocortex cells. Air bubbles are present from 
the coverslip procedure. The third ventricle (red box) is the location that most IHC pictures 






IHC was carried out to validate the presence of the Bdnf protein within the 
neocortex and to compare Bdnf protein levels between brain slices that were 
treated and untreated with propofol for t=4 hours. 
 
IHC with the Santa Cruz Bdnf N-20 antibody produced sections that had a 
uniform green fluorescence that was also observed at the similar levels in the 
negative control sections as shown in Figure 34. This tissue was fixed in 
4% PFA overnight at 4 °C prior to being frozen in OCT for sectioning to 
preserve the tissue. 
 
 
Figure 34: IHC Microscopy Section of an Untreated M ouse Brain with N-20 Antibody.  
FITC secondary antibody at 40X magnification. 1) Third ventricle 1:1000 secondary antibody 
concentration. 2) Dentate gyrus 1:500 secondary antibody concentration. 3) Dentate gyrus 
negative control containing no primary antibody. The background is high in these sections 
with the negative control having just as high background. Fixing of the tissue before 
sectioning could have been the cause. 
 
Fixation of the brain tissue before being frozen in OCT was removed to reduce 
the background noise. After the brain tissue was removed from the euthanised 
mouse it was placed directly into the cryostat mold, covered with OCT liquid 
and snap frozen. Removing the tissue fixing step reduced the background 





Figure 35: IHC Microscopy Sections of Untreated Mou se Brain with N-20 Antibody, No 
Tissue Fixation, 30 Minute Section Fixation. Alexa Fluor® 488 secondary antibody at 40X 
magnification. 1) Third ventricle 1:2000 secondary antibody concentration. 2) Section 1 
overlaid with DAPI stain. 3) Third ventricle negative control. Background is lower compared 
to the sections that were fixed before going into OCT. Negative control has formaldehyde 
fluorescence around the debris in the middle of the third ventricle. 
 
Based on the western blot analysis for the Santa Cruz Bdnf N-20 antibody it 
was decided to switch antibodies and use the Abcam ab72439 antibody for 
IHC. 
 
The section fixation step was reduced from 30 minutes to 10 minutes in 
4% PFA. Antigen retrieval was carried out for three minutes in a pH 6.0 citric 
acid buffer as advised by Abcam. However, the Bdnf antibody did not bind to 
target protein as shown in Figure 36. 
 
 
Figure 36: Microscopy Sections of Mouse Brain with Abcam ab72439 Antibody and 
10 Minute Fixation Time. Alexa Fluor® 488 secondary antibody at 100X magnification. 1) 
Third ventricle 1:2000 secondary antibody concentration. 2) Section 1 overlaid with DAPI 






Background noise had been further reduced by reducing the section fixation 
time. The three minute antigen retrieval may not have been long enough to 
unmask the epitope so this step was increased to ten minutes boiling in pH 6.0 
citric acid buffer. Polylysine coated slides were used instead of gelatin coated 




Figure 37: Microscopy Sections of Mouse Brain with Abcam ab72439 Antibody, 10 
Minute Fixation Time and Commercial Polylysine Slid es. Alexa Fluor® 488 secondary 
antibody at 100X magnification. 1) Third ventricle 1:2000 secondary antibody concentration. 
2) Section 1 overlaid with DAPI stain. 3) Third ventricle negative control. No discernible 
binding of the secondary antibody is demonstrated. 
 
Background noise had been completely eliminated, however there was no 








4.1 Experimental Set Up 
 
Experimental conditions after anaesthetic exposure were kept identical to the 
in vivo study (Laura Bell, UoW, NZ; 2014) to reduce variation between in vivo 
and in vitro brain samples. Animals were sacrificed at similar times and the 
brains were placed into ice-cold nACSF to minimise environmental shock while 
being transported to the Cortical Research Laboratory. Four hundred 
micrometre thick coronal sections were used to allow the anaesthetics to 
completely perfuse through the in vitro tissue slice. Brain slices were kept in 
Mg-deficient ACSF to induce seizure-like activity. This electrical activity in the 
brain slice was measured to ensure each slice was still viable, and able to 
continue to carry out cell functions, e.g. gene expression, while determining if 
the anaesthetic exposure was having the expected inhibitory effect on SLE 
activity. All SLE activity was blocked within 2 hours of anaesthetic exposure 
and a pilot experiment was conducted (Logan Voss, UoW, NZ; 2015) which 
tested that SLE activity returned after a 4 hour exposure to anaesthetics to 
show that the decline in SLE activity was not due to tissue death but due to the 
anaesthetics. Our criteria for a viable slice was that at least four of the six 
recorded locations showed SLE activity. This criteria was not based on 
empirical evidence for viable tissue, but on the fact that having four out of six 
locations active meant that the majority of the tissue was viable. We attempted 
to take slices only from the posterior side of the brain to reduce gene 
expression differences due to different areas of the brain. However if a 
posterior slice had insufficient activity then slices were taken from the anterior 
section of the brain. The time spent in the Mg-deficient ACSF was kept constant 
between all slices to reduce expression differences related to stress on the 
 
73 
brain slices. Carbogen was used to oxygenate and stabilise the pH of the 
ACSF. During the propofol exposure period, nACSF was fed into the bath 
enclosure containing the brain slice through a gravity fed drip system which 
had a constant flow rate between all slices of 5 mL/min. Sevoflurane exposure 
was accomplished through a syringe pump system which pumped at a flow rate 
of 5 mL/min. A sample size of n=5 animals was chosen because of time 
constraints but also to attempt to gather enough data to have statistically 
significant results. From each animal a t=0 hour control, t=4 hour control and 
t=4 hour treatment slice was taken. Only the treatment slice was exposed to 
propofol or sevoflurane. A post hoc sample size calculation was carried out 
using G Power software package (Faul, Erdfelder, Lang and Buchner, 2007) 
which showed that a sample size of n=25 animals for each anaesthetic would 
be required to form statistically accurate data for all changes in expression 81. 
 
4.1.1 Propofol Experiment 
Propofol was mixed with intralipid, the vehicle used for clinical intravenous use, 
and diluted into ACSF to a final concentration of 10 µg/mL. This concentration 
of propofol was higher than clinically relevant intravenous levels due to propofol 
diffusing slowly through brain tissue that is devoid of a blood supply. However, 
this produced propofol concentrations within the brain slices corresponding to 
those achieved in vivo 34. The flow rate was kept constant between slices to 
ensure similar concentrations of propofol within the tissue. 
 
4.1.2 Sevoflurane Experiment 
To deliver the vapour anaesthetic sevoflurane it was added to 50 mL of nACSF 
in a syringe and pumped into the bath containing the brain slice. The level of 
sevoflurane in the ACSF was at a clinically relevant concentration of 1 MAC as 
shown by previous studies 5, 11. A vapouriser could be used to allow for a more 
accurate concentration of sevoflurane and simpler delivery; however, one 




4.2 RNA Quantification and Qualification 
 
RNA qualification and quantification was carried out to ensure good quality 
RNA, as low quality RNA would compromise results from quantitative analysis 
including qPCR analysis, and equal loading of RNA template in downstream 
applications. The NanoDrop™ 2000 Spectrophotometer was used to assess 
quality and quantity of 30 RNA samples and agarose gel electrophoresis was 
also used to determine that the 10 t=0 hour control RNA samples were not 
degraded. 
 
4.2.1 Spectrophotometer Analysis 
Spectrophotometer analysis can determine the quantity and purity of DNA and 
RNA within a sample. This is accomplished by absorbance ratios of the 260 nm 
and 280 nm wavelengths which compares the quantity of RNA or DNA in a 
sample to contaminants such as proteins. The target absorbance ratio is 
between 1.8 and 2.0 which qualifies the RNA sample to be considered pure or 
lacking contaminants. Sample P5T4C had a low absorbance ratio at 1.73. This 
is most likely because of phenol carryover from the TRI Reagent® extraction 
process. A second 75% ethanol wash step could be added to the end of the 
RNA extraction protocol to further reduce the phenol carryover and consistently 
get high A260/A280 ratios. However, this was not done as the P5T4C sample 
was the only sample that had an absorbance ratio outside of the target range. 
S5T0C had a low RNA concentration at 164.1 ng/µL. This would have most 
likely been from not successfully separating all of the aqueous layer which 
contained the RNA during the extraction protocol or excessive drying of the 
RNA pellet; therefore, receiving less RNA template. 
 
In place of the NanoDrop 2000, a bioanalyser could be used to achieve more 
accurate readings of RNA quantity and quality. A bioanalyser is considered 
more accurate due to the RNA integrity number (RIN) algorithm which takes 
into account the complete RNA spectrum and not just the 18S and 28S rRNA 
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regions 82. A RIN is produced ranging from 1 to 10 where 1 is the most 
degraded on this scale while 10 is the most intact. Also, using computer 
software to qualify the integrity of an RNA sample removes human error that is 
associated with gel electrophoresis data. 
 
4.2.2 Non-Denaturing Gel Electrophoresis 
Agarose gel electrophoresis was carried out to assess the quality of the RNA 
template. All samples were not run because there was not enough RNA sample 
to analyse on an agarose gel and complete the qPCR analysis. Therefore, the 
zero hour controls were used to infer the quality of the samples used for qPCR 
analysis. Non-denaturing gel electrophoresis was used instead of denaturing 
formaldehyde gel electrophoresis because the stock of formaldehyde and 
MOPS buffer was of poor quality (Linda Peters, personal communication, April 
9th, 2015). Inclusion on an RNA molecular weight ladder on a denaturing gel 
will resolve the RNA as single stranded ribosomal bands, preventing the 
formation of any secondary structures. Thus, the 18S and 28S will migrate at 
the true size of 1869 bp and 4712 bp respectively, where the 28S band is 
roughly twice as bright as the 18S band. This demonstrates that the RNA is 
intact and has not degraded. An alternative, cheaper and less time-consuming, 
method was to use standard non-denaturing TAE gels to examine if two sharp 
bands representing the 18S and 28S ribosomal bands were present. The first 
RNA sample extracted did not show the two expected bands but instead a 
smear on the gel. The DEPC-treated water used to resuspend the RNA after 
extraction was replaced and all subsequent RNA samples showed no smearing 
on the gel. Both the propofol and sevoflurane t=0 hour control RNA samples 
were run on gels and the two rRNA bands were seen. Thus, data suggests the 
RNA was intact and suitable for downstream application. 
 
In place of the denaturing formaldehyde gel electrophoresis, bleach gel 
electrophoresis could have been carried out. This involves the use of a TAE 
agarose gel containing 0.5 – 1% bleach and has been shown to produce bright, 
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sharp bands with 1 µg of RNA. Bleach has been postulated to denature the 
secondary structures of RNA and destroy any RNases that are present within 
the electrophoresis setup and reagents. Bleach gel electrophoresis allows the 
rapid analysis of RNA quality without the use of toxic chemicals used in 
denaturing formaldehyde gels 83.  
 
Alternatively, a new molecular method published this year using differential 
amplicons (∆Amp) to assess RNA degradation could be used. This measures 
∆Amp of a reference gene and an Endogenous RNase Resistant (ERR) within 
an RNA sample. The degree of RNA damage is reflected by the difference of 
the differential expression of the reference gene to the ERR marker. This 
method is more powerful for analysing RNA degradation compared to the 
bioanalyser as it assesses the mRNA damage where the bioanalyser is 
dominated by rRNA 84. 
 
4.2.3 Genomic DNA Contamination 
Before cDNA synthesis, each sample subjected to a DNAse treatment protocol 
due to TRI Reagent® RNA extraction not removing all genomic DNA. Standard 
PCRs were run with the cDNA –RT controls to confirm all genomic DNA had 
been removed from the sample. Genomic DNA contamination persisted after 
the DNAse treatment so the protocol was changed and the 37 °C incubation 
step was increased from 15 minutes to one hour. This increase in DNAse 
treatment time consistently removed all genomic DNA from the RNA samples. 
A non-exon boundary primer was used to assess the level of genomic DNA in 
the -RT control. This primer was for the housekeeping gene Gapdh. Gapdh 
and B2m housekeeping gene primers used to verify the ability to amplify up the 
cDNA template if successful cDNA synthesis had occurred. Bdnf primer was 
included to see whether or not Bdnf could be amplified; however, this was not 
used as an indication of the presence of Bdnf. If there was no amplification of 
Bdnf with standard PCR the sample was still used in qPCR analysis because 
of its higher sensitivity. 
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4.3 Quantitative PCR Analysis 
 
Quantitative PCR was used to measure the relative expression of our genes of 
interest, Bdnf and Arc. These two genes were chosen based on data published 
(Laura Bell, UoW, NZ; 2014) regarding a study that showed that Bdnf and Arc 
were differentially expressed after anaesthetic exposure to a mouse brain in 
vivo. Also, based on the role these two genes have in memory consolidation 22, 
45. The Bdnf and Arc primers used in this study were previously sequenced by 
Laura Bell. RNA was extracted from only 12 mg of tissue, which made template 
cDNA sample volume an issue. This forced us to dilute the cDNA samples to 
a concentration of 1:5. This provided enough sample volume for all qPCR runs 
and a buffer for qPCR runs that had to be repeated. 
 
No-template controls were run to verify there was no contamination of the PCR 
reaction. Contamination did occur, particularly in the Actb runs. This may have 
been because Actb is a commonly used primer in the Laboratory of Molecular 
Genetics and so Actb product is spread throughout the lab as an aerosol. Steps 
were taken to prevent contamination which included use of a PCR hood, not 
wearing a lab coat, which could have harboured contaminating amplicons, and 
using DEPC-treated mQH2O. If contamination occurred then the run was 
repeated, but with primer solutions being remade. Non-amplification occurred 
in one replicate of a sample during two different qPCR runs, which was most 
likely from human error during pipetting of the cDNA template. When this 
occurred, the run was also repeated. 
 
According to the MIQE guidelines at least 2 reference genes are needed to 
normalise qPCR data 68. A reference gene must be expressed equally 
throughout different pathophysiological conditions to be used in qPCR 
normalisation. Gapdh, β2m, Actβ and HPRT1 reference gene primers were 
used for qPCR normalisation. These genes were chosen because they were 
confirmed to be reference genes in previous studies 69, 79, 80. 
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The qPCR assay conditions were validated by Keiran Oxton (UoW, NZ; 2013) 
and Laura Bell (UoW, NZ; 2014). A melt at 80 °C was included in every qPCR 
cycle before fluorescent acquisition to remove primer dimers which gives a 
more accurate quantification. 
 
4.3.1 Melt Curves 
Melt curves were included at the end of a qPCR run to assess the product or 
products formed during the qPCR run. The melt graph was formed using the 
negative first derivative of the melting curve from the melt cycle. The negative 
first derivative was graphed to give a clearer indication of where the melting 
point is located. The melting point is the temperature at which 50% of the 
dsDNA has been dissociated. A melting point of a product is determined from 
the length of the sequence and the GC content of the sequence. As G-C bonds 
contain three hydrogen bonds compared to the two hydrogen bonds of an A-T 
bond, a sequence with a higher GC content will have a higher melting point. 
Because of this we are able to determine if two products differ more accurately 
than through gel electrophoresis. 
 
If a NTC amplified up above baseline then the product melting point was 
examined to determine if the product was the same as the one present in the 
samples. If the products differed then the sample was not repeated and the 
data was used in the statistical analysis. 
 
4.3.2 Statistical Analysis 
The ∆∆Ct method of qPCR analysis was used. This method uses Ct values 
which are cycle numbers based off of a threshold set on the computer. The 
geometric mean of all the control gene Ct values are taken away from the Ct 
values of the genes of interest for both the control samples and the treatment 
samples to give a ∆Ct value. The ∆Ct of the control samples are taken from the 
∆Ct value of the treatment samples to give a ∆∆Ct value and the fold change 
difference for a gene of interest is 2(-∆∆Ct) 85. Equation 1 provided the formula 
for the ∆∆Ct method. 
 
79 
Each reference gene was subsequently removed from the geometric mean and 
then replaced to ensure that one reference gene was not skewing the data. If 
one of the reference genes skewed the data then this would indicate that that 
particular reference gene changed due to the different pathophysiological 
conditions between the control and treatment samples and would not be 
suitable as a reference gene 86. 
 
The different relative expression levels of both Bdnf and Arc varied greatly 
between samples within the propofol and sevoflurane experiments. With a 
sample size of n=5 a fairly accurate average was seen; however, there were 
some outliers that showed the opposite change in gene expression compared 
to the overall average. This could be due to the differences in expression 
profiles between the posterior and anterior side of the neocortex. We aimed to 
take slices from the same area of the brain for each sample; however, this was 
not always possible if there were no viable slices from the posterior side of the 
brain. Another explanation is that a difference in SLE activity or subtle 
variations in tissue health, which was not assessed by our viability criteria, 
could have affected expression levels within the brain. Having a higher SLE 
activity may have amplified the effect that a general anaesthetic had on the 
brain slice. 
 
4.3.3 In vitro Gene Expression Analysis of Brain-Derived Neurotro phic 
Factor 
Brain-derived neurotrophic factor is a protein in the neurotrophin family which 
is important in neuron survival and encouraging the formation of new neurons 
and synapses 42, 43. It has been shown that the transcription of Bdnf is required 
for maintenance of late-phase LTP and so may be necessary for memory 
consolidation and recall 50. Lowered Bdnf levels has been linked to 
neurodegenerative diseases including Alzheimer’s disease, Huntington’s 
disease, Parkinson’s disease and dementia, but also mental illnesses such as 




Our gene expression analysis on Bdnf after a t=4 hour exposure of propofol 
shows a downregulation of the gene by factor of 0.71; however, this was not 
statistically significant. Previous studies has shown that Bdnf mRNA levels are 
decreased in rat hippocampal neurons from GABAergic stimulation after 
neuronal maturation. Due to propofols proposed mechanism of action of GABA 
enhancement, it is possible that this is one of the causes of reduction in Bdnf 
levels 91. It has also been shown that Bdnf mRNA is down regulated upon 
activation of the 5-HT receptors (serotonin receptors); therefore, general 
anaesthetics could increase the level of serotonin within the brain which 
activate these 5-HT receptors, thereby reducing Bdnf expression 92, 93, 94. 
 
Bdnf directly activates NMDA receptor subunit one through phosphorylation 
and NMDA receptor subunit 2-β through the Fyn signaling pathway 95, 96. 
Activation of NMDA receptors causes molecular changes that are required in 
the formation of new memories. A reduction in Bdnf levels would decrease the 
activation of NMDA receptors and, therefore, impede the formation of new 
memories 97. This can explain the loss of memory consolidation both during 
and after surgeries where propofol is used. An increase in NMDA receptor 
activity can form new memories but the AMPA receptors maintain the synapses 
communication, structure and function long after the initial activation of the 
NMDA receptors and channels. Bdnf has been shown to upregulate the AMPA 
receptors, GluR1 and GluR2 through the TrkB pathway 98, 99. A reduction in 
Bdnf levels would decrease the number of AMPA receptors and, therefore, 
reduce the likelihood that a new memory is consolidated to long term memory. 
This would explain the amnesic effect that propofol has on patients before it is 
administered. 
 
We observed an upregulation of Bdnf after t=4 hour exposure of sevoflurane 
by a factor of 1.86; however, this was not statistically significant. Bdnf has been 
shown to be upregulated in the hippocampus of epileptic patients after a 
 
81 
seizure 100. An increase in Bdnf during the anaesthetic exposure time could be 
due to the seizure-like activity that is induced within the tissue to ensure the 
tissue was still viable. However, the propofol samples had a decrease in Bdnf 
expression but it may be that the net decrease of Bdnf expression due to GABA 
enhancement and activation of the 5-HT receptors is greater for propofol than 
for sevoflurane. 
 
4.3.4 In vitro Gene Expression Analysis of Activity-Regulated 
Cytoskeleton-Associated Protein 
Activity-regulated cytoskeleton-associated protein is a protein from the 
immediate-early gene family. Arc is expressed after a learning experience and 
rapidly transported to dendrites. Arc plays a role in neuronal plasticity through 
the endocytosis of AMPA receptors, regulation of cell morphology, cytoskeletal 
organisation and modulating dendritic spine remodeling and density 52. Arc has 
been implicated in neurological conditions such as amnesia, Alzheimer’s 
disease, and autism spectrum disorders 101, 102. 
 
Our gene expression analysis on Arc after a t=4 hour exposure of propofol 
showed an upregulation of the gene by factor of 1.56; however, this was not 
statistically significant. Arc is regulated by many different pathways including 
Bdnf 52, 103. As we see Bdnf is down regulated in the propofol experiments, we 
might expect Arc to also be down regulated; however, this is not the case. Arc 
being up regulated could be due to its ability to be managed by proteins and 
pathways outside of the neurotrophic family of proteins. These proteins include 
epidermal growth factor and nerve growth factor but also the glutamate binding 
to NMDA receptors and dopamine binding to dopamine receptor D1 104, 105, 106. 
Therefore, a reduction in Bdnf levels could be rectified by activating a wide 
range of other pathways to save Arc levels. 
 
We observed a downregulation of Arc after t=4 hour exposure of sevoflurane. 
This downregulation was by a factor of 0.348 and was statistically significant 
with a p-value of 0.003. This data agrees with previously published data by 
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Kobayashi et al. (2007) who also noted a downregulation of Arc in response to 
sevoflurane induced anaesthesia. Arc is expressed after activity at the 
synapse, and when this activity is reduced due to general anaesthesia, it is 
expected that there will be a reduction in Arc mRNA levels 54. Actin is a protein 
which forms microfilaments. In its filamentous form (F-actin), it is used for cell 
signaling and remodeling of cells 107. As synaptic plasticity requires NMDA and 
AMPA receptors to be moved to synaptic sites, the F-actin molecules are used 
for this protein movement within the synapses. A decrease in Arc levels may 
inhibit the formation of F-actin and, therefore, stop synapses from being 
remodeled for synaptic strengthening. This would stop the consolidation of 
short term memory into long term memory. Arc also modulates dendritic spine 
density which creates more synaptic sites for memory consolidation 108. 
Reducing Arc levels may possibly stop the formation of new synaptic sites and 
therefore stop the formation of new memories. 
 
4.3.5 Gene Expression Differences between In vitro and In vivo 
Data from both the t=4 hour propofol in vivo exposure study conducted by 
Laura Bell (UoW, NZ; 2014) and our in vitro study showed a slight 
downregulation of Bdnf, but neither result was statistically significant. In the 
t=4 hour sevoflurane in vivo exposure study showed a statistically significant 
decrease in Bdnf mRNA levels while our t=4 hour sevoflurane in vitro found an 
increase in Bdnf mRNA levels. Arc mRNA levels after a t=4 hour in vivo 
propofol treatment showed a statistically significant increase. Our experiment 
also found an increase in Arc mRNA levels after a t=4 hour propofol in vitro 
exposure. No change in Arc mRNA levels after a t=4 hour in vivo sevoflurane 
treatment were seen, while after a t=4 hour sevoflurane in vitro exposure a 
statistically significant decrease in Arc levels was seen. These results are 
shown in Table 19. 
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Table 19: Gene Expression Differen ce between In vitro and In vivo. ↑ signifies 
upregulation. ↓ signifies downregulation. – signifies no change. Only the results marked by 
a * were shown to be statistically significant (p<0.05). 
 In vitro In vivo 
Bdnf  Arc  Bdnf  Arc  
Propofol  ↓ ↑ ↓ ↑* 
Sevoflurane ↑ ↓* ↓ - 
 
 
Bdnf has been shown to be up regulated in epileptic patients due to seizures 
100. As our in vitro experiment required the induction of seizure-like events in 
the brain slices to verify the validity of the tissue, these seizures may have been 
the cause of increase Bdnf levels in the in vitro experiment. For the in vivo 
experiments the whole neocortex was collected for RNA extraction while the 
in vitro experiment used slices to ensure complete perfusion of the general 
anaesthetics. We saw a difference between individual slices from the in vitro 
experiments and, recently, single cell transcriptomic work has shown that cells 
in close proximity can have different transcriptomes. Therefore, the differences 
we see between the in vivo and in vitro work could be due to the fact that the 
in vivo experiment effectively took an average transcriptome of the whole brain 
while we took the transcriptome of the posterior side of the brain 109, 110. 
 
4.4 Detection of Protein Expression  
 
IHC was performed for detecting protein level localisation within the neocortex, 
and western blots to validate the primary antibodies that were going to be used 
on whole tissue mouse brain extracts. The Santa Cruz N-20 Bdnf polyclonal 
antibody was selected based on its high citation record in the literature. We 
expected to observe a band at either 14 kDa or 32 kDa. However, we observed 
a 55 kDa band on our western blot using this antibody against epitope sample 
of whole brain mouse lysate. The larger band may have been from off-target 
binding due to the antibody being polyclonal or protein polymer formation. 
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Off-target binding would be to other proteins within the neurotrophin family 
which includes; Nerve Growth Factor (NGF), Neurotrophin-3 (NT-3) and 
Neurotrophin-4 (NT-4). All of these neurotrophins have similar protein 
structures. To attempt to improve antibody recognition as intended, we first 
increased the β-mercaptoethanol concentration in the sample buffer in order to 
help break bonds between potential protein polymers. This did not change the 
western blot and a band at 55 kDa was still produced with no sign of a band at 
the predicted sizes. An increase in protein concentration (50 µg to 100 µg) was 
used to remove the possibility of the predicted band sizes being lost due to low 
protein concentrations. Whole tissue extracts from five other mouse organs, 
which included; heart, lung, kidney, spleen and liver, were also run on a 
western blot to remove the possibility of the antibody binding to a Bdnf protein 
that has different protein splicing or post-translational modifications not present 
within the mouse brain. No bands at the predicted sizes were seen but an 
increasing intensity of the 55 kDa band was observed as protein concentration 
was increased. A western blot was run with the Genetex GTX110564 
Beta-actin antibody which produced a band at the correct size of 42 kDa 
indicating that the western blot procedure was not flawed. Also a 
non-denaturing PAGE gel was used to ensure that the denaturing gel was not 
removing the epitope that the Bdnf antibody recognised (data not shown). The 
same result was produced with a single band at 55 kDa. Lastly, an increase in 
primary antibody concentration, from 1:1000 to 1:100, was used which 
produced the same results as increasing the protein concentration. Protein 
transfer from the SDS-PAGE gel to the PVDF membrane occurred correctly as 
evident from the Ponceau S staining. In conclusion, this antibody did not 
recognise its expected epitope and generate bands of the expected size. It was 
noted that this antibody was not stored correctly upon arrival and thus, the 
stability of the antibody may have not been optimal (Linda Peters, personal 
communication, January 15th, 2015). Therefore, a new antibody, Abcam 




The Abcam polyclonal ab72439 antibody produced western blots with the 
expected size of 28 kDa. There were other bands on this gel which could be 
attributed to a high secondary antibody concentration. Decreasing the 
secondary antibody concentration or increasing the final wash step duration 
would remove these extra bands. The positive result was replicated and the 
antibody was validated. The Abcam antibody was then used in IHC to 
determine areas and levels of Bdnf expression within the mouse brain. 
 
4.5 Hematoxylin and Eosin Staining 
 
H&E staining was used to detect changes in cell morphology within the mouse 
brain between a control section and a treated section. It was also used to 
counter stain IHC sections to enable us to determine the cell type we were 
viewing under fluorescence. Ten micrometre thick mouse brain coronal 
cryosections were sectioned in a cryostat from a whole mouse brain and placed 
onto commercial polylysine slides. H&E staining procedure was used to 
examine the histological appearance of the cells. The H&E stained sections 
showed the anatomy of the mouse brain coronal section clearly. The nuclei rich 
areas of the neocortex and hippocampal formation were stained blue by the 
hematoxylin. This indicated that the cryosection procedure produced sections 
with intact cells.  
 
There was folding and tearing of the tissue during the cryosectioning procedure 
which meant that no clear and complete sections were produced. Molds 
containing the brain tissue in OCT were snap frozen and placed into a -80 °C 
freezer to ensure the tissue was completely frozen. A new blade was used and 
sectioning at -30 °C and – 15 °C was attempted with no improvement to the 
folding and tearing of the tissue. Also, sectioning at a thickness of 5 µm instead 
of 10 µm did not improve the section quality. Tissue from multiple different mice 
were used with no difference in the quality of sections. Further optimisation of 





IHC was carried out to validate the presence of the Bdnf protein within the 
neocortex, and to compare Bdnf protein levels between brain slices that were 
treated and untreated with propofol for t=4 hours. All of the IHC pictures were 
taken at the center of the corpus callosum, including part of the third ventricle 
for comparison. 
 
No fluorescence above baseline, which was established from control slides that 
contained no primary antibody, was identified in any of the microscope 
sections. However, the DAPI stain worked correctly and stained the nuclei 
bright blue. A wide range of problems were encountered during IHC and 
Table 20 outlines the troubleshooting methodologies used to try an overcome 
these issues 
Table 20: Troubleshooting IHC Problems . 
Sections tearing and 
folding 
Cutting temperature trailed at -15 °C, -25 °C and 
-30 °C 
High background 
Removed tissue fixation in 4% PFA before 
cryosectioning. 
IHC protocol fixation reduced from 30 minutes to 
10 minutes. 
Blocking solution was changed from 5% goat 
serum to Lifetech Blockaid. 
Changed from handmade gelatin-coated slides to 
commercial polylysine coated slides. 
N-20 antibody not 
binding to Bdnf 
Primary antibody concentration gradient from 
1:1000 to 1:100. Secondary antibody kept at 
1:2000 as advised by the manufacturer’s data 
sheet. 
Overnight incubation of slides in primary antibody 
at 4 °C. 
Ab72439 antibody 
not binding to Bdnf 
Increased antigen retrieval boiling time. 
Increased primary antibody concentration from 






We successfully removed all background with reducing the fixation times and 
changing from handmade gelatin coated slides to commercial polylysine 
coated slides. However, we were unable to detect a positive green Bdnf signal 
within the brain tissue sections. Reintroducing the dehydration step that was 
removed after tissue was placed directly into OCT would cause the tissue to 
be more stable and perhaps not tear as much. Further increasing antigen 









The aim of this study was to identify changes in the expression, within the 
neocortex, of the memory-related genes, brain-derived neurotrophic factor 
(Bdnf) and Activity-regulated cytoskeleton-associated protein (Arc), after a four 
hour exposure to the commonly used general anaesthetics propofol and 
sevoflurane. An in vitro mouse model was used and each anaesthetic 
contained a sample size of five mice. Quantitative polymerase chain reaction 
(qPCR) was used to analyse the changes in gene expression between the four 
hour exposure samples and time-matched four hour controls. 
 
Our data showed that after a t=4 hour exposure to propofol, Bdnf was down 
regulated by a factor of 0.710 while Arc was up regulated by 1.560. Following 
a t=4 hour exposure of sevoflurane, Bdnf was up regulated by a factor of 1.859 
and Arc was down regulated by 0.348 which was statistically significant 
(p<0.05). Because of the roles that Bdnf and Arc play in memory consolidation 
this provides an indication on how synaptic plasticity is affected when the 
regulation of these two genes changes. With synaptic plasticity being disrupted, 
this leads to the amnesic effect that is seen with administration of general 
anaesthetics. 
 
Also the expression differences between an in vivo and in vitro mouse model 
was investigated. After a t=4 hour exposure to sevoflurane, Bdnf was shown to 
be down regulated in vivo while being upregulated in vitro. This may have been 
due to the differences in tissue preparation of the in vitro study and instead of 
an unknown interaction that is only present in vivo. Arc was shown to have no 
change in regulation in vivo while in vitro had a significant downregulation 








Based on the outcomes of this study, eleven future recommendations have 
been made and these are discussed in more detail below.  They will ultimately 
depend on budget restrictions.  
 
6.1 Varying Induction and Maintenance Anaesthetics  
 
Both propofol and sevoflurane were used in clinically significant concentrations 
during this study. During clinical application of general anaesthetics, it is most 
common to use multiple anaesthetics during an operation. Propofol is often 
used to induce anaesthesia while sevoflurane is used to maintain anaesthesia. 
Therefore, to match more closely to a clinical application an in vivo gene 





It has been shown that epigenetics plays a role in the expression levels of Bdnf. 
One study found that Bdnf was down-regulated after chronic exposure to 
opiates due to epigenetic modification at specific Bdnf gene promoters 111. 
Epigenetic differences within a population may affect the expression 
differences between patients receiving anaesthetics. This could modify their 
sensitivity to anaesthetics or exacerbate adverse effects such as postoperative 
cognitive dysfunction. Comparing epigenetic modifications of memory-related 
genes and their promotors, e.g. Bdnf, between mice within a single strain could 
help elucidate the mechanisms of action for anaesthetic side effects. DNA 
methylation can be detected using Bisulphite genomic sequencing 112. 
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6.3 Measure Gene Expression Post-Anaesthetic Exposu re 
 
Postoperative cognitive dysfunction (POCD) is a decline in cognitive function 
that can last from a few days to a few weeks. Symptoms include amnesia, 
confusion, reduced awareness and attention. This is one of the negative side 
effects of general anaesthetics. Gene expression analysis should be carried 
out to analyse the mRNA expression differences 24 hours and 48 hours post 
anaesthesia. As POCD occurs most commonly in elderly patients, expression 
differences between young (aged 4 - 8 weeks old) and elderly mice 
(aged 18 - 22 months) should also be investigated. Alzheimer’s disease 
transgenic mice have been previously used as a model for POCD 113. An 
increase in β-amyloid levels in 9-month old Alzheimer’s transgenic mice was 
detected and they also showed cognitive impairment in the Fear Conditioning 
System (FCS), indicating POCD, while wild-type mice showed no change. 
Examining the expression differences of memory-related genes between the 
Alzheimer’s transgenic mice and wild-type mice may help elucidate causes of 
POCD.  
 
6.4 Behavioural Studies 
 
Bdnf expression has been shown to be reduced in patients with depression 114, 
115. Mice involved in gene expression studies that have major depressive 
disorder could cause a difference in expression results. Behavioural tests can 
determine the level of depression within a mouse. Forced-swimming test 
places a mouse inside an inescapable cylinder filled with water. Mice that stop 
performing escape-directed behaviours and become immobile faster are 
considered more depressed 116. Tail suspension test is another depression 
behavioural test where a mouse is suspended by the tail. Just like the 
forced-swimming test, the longer the immobility time, the more depressed a 
mouse is 117. Using these two tests a level of depression can be recorded and 
expression analysis can take these into consideration to determine if the 




6.5 Bdnf Knockout Mice 
 
Bdnf has been shown to play a role in activity-dependent synaptic plasticity 49. 
Bdnf modifies expression of other memory-related genes such as Arc and is 
important in neuronal development and survival 50. Knockout Bdnf die during 
the perinatal period therefore a heterozygous Bdnf mutant would be required 
118. Previous studies have shown that Bdnf expression is required pre- and 
postnatally for synaptic plasticity and normal behaviour 119. Heterozygous 
mutant Bdnf mice have severe deficiencies in coordination, balance and show 
reduced basal synaptic transmission 118, 120. Bdnf mutant mice may have 
differing pathways to some form of synaptic plasticity and therefore 
transcriptome analysis should be carried out to compare mutant mice and 
wild-type mice. 
 
6.6 Investigate Differential mRNA Expression within  the 
Mouse Brain 
 
Expression differences between each sample within an anaesthetic experiment 
varied greatly. In the propofol experiment there was a range from Arc being 
down regulated by 0.89 to an upregulation of 2.52. This variation could be a 
result of where the slices were taken from within each brain slice. We attempted 
to gather posterior sections, but due to our selection criteria this did not always 
occur and some medial sections were taken. Exploring the gene expression 
differences between the different areas of the neocortex could uncover whether 
or not Bdnf and Arc play a greater role in memory consolidation in certain areas 




6.7 Role of Brain Activity  
 
Differences in activity within the mouse brain may effect gene expression 
levels. Increased SLE activity may indicate more active tissue where the effects 
of general anaesthetics are amplified. An analysis of gene expression 
compared to SLE activity should be investigated. If SLE activity does change 
gene expression then the results of slice studies may be skewed. 
 
6.8 Whole Transcriptome Analysis using RNA-Sequenci ng 
 
RNA-Seq is a powerful whole transcriptome analysis technique that reveals the 
quantity of every RNA present within a sample at a given time. RNA-Seq can 
also elucidate isoforms, splice variants and fusion genes 121. The use of 
RNA-Seq in this study would be useful as it could identify other genes, and 
their isoforms, that have their regulation changed due to the anaesthetic 
exposure. All of the genes that have variable expression due to anaesthetics 
could be cross examined to known memory-related genes, such as Bdnf, Arc 
or neurotransmitter receptors, to identify genes that have the highest variation. 
This would help elucidate the reasons for memory loss due to anaesthesia. 
RNA-Seq is preferred over other transcriptome sequencing platforms, 
e.g. microarray sequencing, as it provides an unbiased detection of RNAs 
within the sample due to not requiring transcript specific probes, a wider 
dynamic range of high-resolution analysis, and the ability to detect rare 
isoforms. Beijing Genomics Institute (BGI) would be contracted to perform 
RNA-Seq and bioinformatics analysis 122. Transcriptomes between single cells 
have shown to be distinct even within similar tissue 109, 110. BGI also offers 
single cell whole transcriptome sequencing, which would allow us to examine 
expression differences between pre- and post-synaptic neurons and how their 
expression varies for synaptic plasticity. As this is also whole transcriptome 
sequencing, novel genes that are related to synaptic plasticity would be 




6.9 Determine Localisation and Level of Protein Exp ression in 
the Brain 
 
In this study we attempted to use IHC to analyse the localisation of the Bdnf 
protein in a coronal brain section and determine if there was a difference in the 
expression levels. Alternatively, western blots could be used to assess the 
protein level of Bdnf between an anaesthetics-treated whole mouse brain and 
an untreated control brain. As mRNA levels do not correlate to protein levels 
this would allow us to examine if the Bdnf protein levels change in a similar way 
to the mRNA levels from the results in this study. Mice would be exposed to an 
anaesthetic for a duration of t=4 hours, sacrificed and the whole brain 
extracted. Whole brain extract could then be run on a 4% - 16% SDS PAGE 
gel, transferred to a PVDF membrane and subjected to the western blot 
protocol outlined in section 2.8. A control whole brain extract sample, which 
has had no anaesthetic exposure, would also be run alongside the treated 
sample to compare Bdnf protein levels to. 
 
6.10 Improve IHC Protocol  
 
IHC is useful to observe where in the brain Bdnf is being expressed with respect 
to cell type and in what levels compared to other areas of the brain. IHC would 
also be used to analyse Bdnf protein levels. We were not successful in 
producing a positive Bdnf protein signal in IHC during this study, however it 
would be beneficial to improve the IHC protocol to obtain a positive signal and 
assess the level of Bdnf between an anaesthetics treated brain slice and an 
untreated control brain slice. To optimise the IHC protocol, antigen retrieval 
conditions could be changed such as increasing the heating duration, using a 
steam pressure cooker instead of a microwave, or trialling different pH antigen 
retrieval buffers like EDTA-NaOH pH 8.0 buffer 123, 124. A positive antibody 
control should be used to ensure the protocol is working correctly. 
Microtubule-associated protein 2 (MAP2) would be an ideal positive control for 
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the neocortex 125. Improving fixation times, dehydration and embedding would 
allow sections to be cut without the tissue tearing or curling. In addition, a 
normal rabbit serum pre-immune control should be included to demonstrate 
specificity of the primary antibodies raised in rabbits. 
 
6.11 Arc Antibody 
 
As Arc expression has also differed with anaesthetic exposure it would be 
valuable to source an anti-Arc antibody for use in IHC and western blots. We 
suggest the Anti-Arg 3.1 antibody (ab23382; Abcam, UK) due to the citations 
that have managed a positive signal in both western blot and IHC. This Arc 
antibody would be useful in western blot analysis comparing protein levels 
between anaesthetic treated and untreated whole mouse brains. It would also 
be useful in comparing the protein levels within the brain using IHC to the levels 
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Appendix 1: Reagents and Solutions 
  
Agarose (1%) Gel with 1X TAE buffer 
To prepare a 1% agarose gel with 1X TAE buffer, add 0.4 g of agarose to 40 mL 
of 1X TAE and dissolve by heating in a microwave oven. When the solution 
has cooled to 60°C, add 1 µL of 10 mg/mL EtBr and gently mix before pouring 
into the level gel tank. Leave for at least 30 minutes to set. 
 
DEPC H2O 
To prepare 0.1% DEPC H2O, add 2 mL of DEPC to 2000 mL of sterile mQH2O 
in the fume hood. The solution should be mixed with a magnetic stirrer in the 
fume hood overnight to ensure all DEPC is completely dissolved. It is important 
to wear gloves and safety glasses and use the fume hood when making this 
solution, as DEPC is a suspected carcinogen. Once the DEPC has been 
dissolved overnight, autoclave the solution on a fluids cycle. Store at RT. 
 
4% Paraformaldehyde 
To 16 mL of mQH2O add 2g Paraformaldehyde stock powder and 6 µL of 
10 M NaOH. Dissolve for one hour in a 60 °C water bath. After completely 
dissolved, add 10 mL of 10X PBS and 10 µL 10 M HCl then adjust to pH 7.4. 
Fill to 50 mL with mQH2O. Filter solution through a 0.45 µm membrane filter. 
Store at 4 °C for up to one month. 
 
EDTA (0.5 M) 
To prepare EDTA at 0.5 M, add 186.1 g of disodium EDTA to 800 mL of 
mQH2O. Stir vigorously using a magnetic stirrer. Adjust pH to desired value 




TAE Buffer (1X) 
To prepare a 50X stock solution of TAE buffer, add 242 g of Tris and 18.61 g 
of disodium EDTA to approximately 700 mL mQH2O and stir until dissolved. 
Add the acetic acid and adjust volume to 1 L. To make a 1X working buffer, 
add 20 mL of the stock solution to 980 mL of mQH2O. 
 
Tris-Cl (1M) 
To prepare a 1M Tris-Cl solution, dissolve 121.1 g of Tris base in 800 mL of 
mQH2O. Adjust pH to desired value with HCl. 
 
Tris EDTA (TE) Buffer 
To prepare Tris EDTA buffer, add 2 mL of Tris (1 M) and 4 mL of EDTA (0.5 M) 
to a sterile bottle. Make up to 200 mL with sterile mQH2O and mix by gentle 
inversion. Store at RT. 
 
PBS Buffer (1X) 
To prepare a 10X stock solution of PBS buffer, add 80 g of NaCl, 2 g of KCl, 
14.2 g Na2HPO4 and 2.4 g of KH2PO4 to 800 mL of mQH2O. Adjust pH to 7.4 
with HCl and then fill to 1 L with mQH2O. To make a 1X working buffer, add 
100 mL of 10X PBS to 900 mL of mQH2O 
 
PBS-T Buffer (1X) 
To make a 1X working buffer, add 100 mL of 10X PBS and 1 mL Tween 20 to 
899 mL of mQH2O. Stir on magnetic stirrer until Tween 20 completely 
dissolved. 
 
TBS Buffer (1X) 
To prepare a 10X stock solution of TBS buffer, add 60.5 g Tris, 87.6 g NaCl to 
800 mL of mQH2O. Adjust pH to 7.4 with HCl and then fill to 1 L with mQH2O. 




TBS-T Buffer (1X) 
To make a 1X working buffer, add 100 mL of 10X TBS and 1 mL Tween 20 to 
899 mL of mQH2O. Stir on magnetic stirrer until Tween 20 completely 
dissolved. 
 
Laemmli Sample Buffer (2X) 
To prepare a 2X working Laemmli sample buffer add 1 mL 1M Tris-HCl, 0.4 g 
SDS, and 2 mL 100% glycerol. Fill up to 9 mL with mQH2O. Add 
10% β-mercaptoethanol freshly before use. 
 
DNA Loading Buffer (6X) 
To a 15 mL Falcon tube, add 3 mL of 100% glycerol, 25 mg of bromophenol 









Appendix 3: Waikato Safety Operating Procedure (SOP ) 9 
 
UNIVERSITY OF WAIKATO ANIMAL ETHICS COMMITTEE 
STANDARD OPERATING PROCEDURE 
SOP Number: 9 
Title: Euthanasia of Rodents by CO2 Asphyxiation 
**Only persons that have received appropriate training and have been 
approved by the Animal Ethics Committee may perform this euthanasia** 
General: 
This procedure outlines the general procedure for euthanizing rodents using 
CO2 gas. 
Equipment Required: 
Building Animal House (Glasshouse compound) has a purpose built chamber 
connected to a CO2 cylinder. 
Setup: 
• Check with the Technician if there are any questions or concerns. 
• Put the cage still containing the animal(s) directly in chamber. It is 
recommended that animals be euthanised in their “home” cages. 
There has been less stress observed if the animal(s) are with familiar 
surroundings and smells. 
• Ensure that the chamber lid is shut 
• It is essential that there is adequate ventilation for the operator. 
• Operation (see diagram): 
1. Ensure needle valve is closed 
2. Open cylinder valve one full turn 
3. Turn regulator until low pressure gauge reads “200” 





• Once the concentration has caused the animal(s) to stop breathing, 
the CO2 may be turned off but the chamber should remain closed for 
10 minutes. 
1. Turn off cylinder valve 
2. Wait for pressure to drop 
3. Loosen off the regulator 
4. Close needle valve 
• After 10 minutes open the chamber and ensure that the animals are 
dead. There should be an absence of breathing, no detectable 
heartbeat and glazed over eyes. 
The chamber has a quite large volume and it may take some time for the 
level of CO2 to rise up to and into the cage tray. 
Alternatives: 
Small numbers of animals: 
Where there are small numbers of animals involved, an effective method is to 
place the cage into a plastic bag and insert the gas hose into the bag and 
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seal it off. Single animals maybe euthanised in a clear lidded bucket that has 
the gas hose inserted. Food wrap or a clear plastic bag over the top works 
well. 
Dealing with large numbers of animals: 
The chamber can only fit a limited number of cages at once. 
The operator: 
1. can rotate the cages through (but chamber must be vented between 
batches; it is painful for the animals to be dunked straight into high 
CO2 concentrations (ANZCART, 2006). 
2. transfer the animals to as few cages as possible; operator must 
carefully check that the animals are all dead. Ones at the bottom of the 
pile may lie in air pockets 
3. let all animals run loose in the chamber (without cages). They will be 
too busy sniffing each other to notice the effects of the gas. The 
operator will then have to clean up the chamber afterward. 
Field work with wild animals: 
The chamber in the Animal House is not portable; therefore field euthanasia 
will have to involve the use of a small CO2 cylinder, regulator, needle valve 
and plastic bag or a custom made chamber (or tube). Use a dark bag so not 
to stress out the animal further. Wild animal respond differently to CO2 and 
may take longer to succumb than lab bred animals. DO NOT bring wild 
animals into Animal House for euthanizing without permission from the 
technician; wild animals carry diseases/parasites which could transmit to lab 
animals being housed in Animal House. 
Adverse Events and Unexpected Outcomes:  Occasionally animals have 
recovered consciousness and/or exhibited signs of life sometime after the 
procedure. They were not fully euthanised but the operator did not observe 
signs of life (wait the full 10 minutes). This possibly is due to the animal(s) 
being at the bottom of a pile and in a lower (insufficient) concentration of 
CO2. The animal(s) must be returned to the chamber (or bucket) without 
delay to complete the euthanasia. 
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Occupational Safety and Health Considerations:  CO2 gas is heavier than 
air. In confined spaces the gas displaces air and could cause asphyxiation to 
the operator in high concentrations. Ensuring ventilation during these 
operations is essential (i.e. open the doors and remain away from the 
chamber when possible, preferably outside). Asphyxiation symptoms may not 
be apparent and their onset may be quick. Refer to the MSDS for more 
information. 
Reference: 
ANZCART, 2006. Report of the International Consensus Meeting on Carbon 
Dioxide Euthanasia of Laboratory Animals. ANZCART News 19:2 1-7 
summarized from the final report prepared by Hawkins, P et al. Copy 




Appendix 4: Raw Expression Data 
 
All raw qPCR data, expression calculations and statistical analysis are on the 
accompanying disc. 
